

CITATION REPORT

List of articles citing

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

DOI: 10.1182/blood-2003-05-1545
Blood, 2004, 103, 275-82.

Source: <https://exaly.com/paper-pdf/37285072/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2300	http://www.spandidos-publications.com/ijo/article.jsp?article_id=ijo_33_3_541 . 1992 , 33, 549		
2299	Hematopoietic and lymphoid tumors. 2000 , 304-388		
2298	Prediction of response and resistance to treatment by gene expression profiling. 2001 , 212-237		
2297	Prognostic factors for lymphomas. 2001 , 32-54		
2296	Diffuse large B-cell lymphoma. 2001 , 168-181		
2295	[Clinical application of gene-expression profiling in lymphoma]. 2004 , 20, 848-50	0	
2294	Transcription Factors Come of Age in Lymphoma Immunophenotyping. 2004 , 122, 173-175		
2293	[New diagnostic and therapeutic strategies for aggressive lymphomas]. 2004 , 129, 2113-7	1	
2292	[Expression profile and prognostic significance of CD24, p53 and p21 in lymphomas. A tissue microarray study of over 600 non-Hodgkin lymphomas]. 2004 , 129, 2094-9		12
2291	Risk assessment in the genomic era. 2004 , 32 Suppl 1, 3-8		7
2290	Durchflusszytometrische Typisierung der B-Zell Non-Hodgkin-Lymphome / Flow cytometric typing of B-cell Non Hodgkin lymphoma. 2004 , 28, 410-423		
2289	A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. 2004 , 91, 141-9		32
2288	Molecular heterogeneity of diffuse large B-cell lymphoma. 2004 , 5 Suppl 3, S144-8		1
2287	Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. 2004 , 17, 847-56		31
2286	Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells. 2004 , 17, 1338-45		19
2285	Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. 2004 , 54, 667-74		18
2284	Lymphoma: Current concepts and difficult diagnostic disorders. 2004 , 54, S303-S317		

2283	Molecular signatures of lymphoma. 2004 , 80, 401-9	10
2282	CD10 expression in diffuse large B-cell lymphomas does not influence survival. 2004 , 445, 545-51	26
2281	Molecular diagnosis in lymphoma. 2004 , 6, 369-79	3
2280	CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. 2004 , 203, 946-52	48
2279	Technology insight: Identification of biomarkers with tissue microarray technology. 2004 , 1, 104-11	104
2278	Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study. 2004 , 43, 758-65	70
2277	Non-Hodgkin's lymphoma in the microarray era. 2004 , 5, 128-9	3
2276	Rituximab in Aggressive Non-Hodgkin's Lymphoma: An Update of Studies Presented at the 2004 American Society of Hematology Meeting. 2004 , 5, 152-154	1
2275	Recent advances in the understanding of aggressive B-cell lymphomas. 2004 , 10, 360-373	3
2274	BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. 2004 , 165, 159-66	232
2273	Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. 2004 , 165, 481-90	102
2272	Bibliography Current World Literature. 2004 , 11, 439-511	
2271	Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. 2004 , 11, 227-38	62
2270	Bibliography. Current world literature. Lymphoma. 2004 , 16, 496-515	0
2269	Emerging prognostic factors in diffuse large B cell lymphoma. 2004 , 16, 436-41	34
2268	Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. <i>Blood</i> , 2004 , 104, 2933-5	2.2 176
2267	Organisation of neoplastic haematopathology services: a UK perspective. 2005 , 37, 479-92	7
2266	Diagnostic pathology of lymphoproliferative disorders. 2005 , 37, 434-56	8

2265	Molecular biology of lymphoma in the microarray era. 2005 , 37, 508-22		6
2264	Current World Literature. 2005 , 5, 91-112		
2263	The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features. 2005 , 13, 116-23		6
2262	Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. 2005 , 2005, 252-9		30
2261	Immunophenotyping of lymphoproliferative disorders: state of the art. 2005 , 37, 457-78		11
2260	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. <i>Blood</i> , 2005 , 105, 2916-23	2.2	75
2259	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. <i>Blood</i> , 2005 , 105, 3979-86	2.2	105
2258	AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. <i>Blood</i> , 2005 , 106, 1762-9	2.2	57
2257	[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. <i>Blood</i> , 2005 , 106, 1376-81	2.2	418
2256	Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. <i>Blood</i> , 2005 , 106, 1164-74	2.2	166
2255	Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. <i>Blood</i> , 2005 , 106, 2491-7	2.2	186
2254	Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. <i>Blood</i> , 2005 , 106, 3383-5	2.2	62
2253	Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. 2005 , 19, 223-34		39
2252	Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. 2005 , 22, 327-41		25
2251	Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry. 2005 , 81, 48-57		12
2250	CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. 2005 , 81, 58-61		4
2249	Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases. 2005 , 46, 217-28		42
2248	Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. 2005 , 46, 241-55		24

2247	CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. 2005 , 46, 328-33	28
2246	Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. 2005 , 47, 281-91	24
2245	The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. 2005 , 128, 333-42	62
2244	Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. 2005 , 128, 813-9	15
2243	T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. 2005 , 19, 652-8	309
2242	FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. 2005 , 19, 1299-305	125
2241	Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. 2005 , 19, 1471-8	25
2240	Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma. 2005 , 19, 1824-30	16
2239	Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. 2005 , 18, 398-405	66
2238	Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. 2005 , 18, 1113-20	171
2237	Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm. 2005 , 18, 1121-6	31
2236	Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. 2005 , 18, 1377-84	106
2235	Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies. 2005 , 40, 737-44	73
2234	Microarray-based classification of diffuse large B-cell lymphoma. 2005 , 74, 453-65	38
2233	Non-mediastinal grey zone lymphomas and report from the workshop. 2005 , 75, 42-4	7
2232	Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. 2005 , 55, 324-30	32
2231	Modern classification of neoplasms: reconciling differences between morphologic and molecular approaches. 2005 , 5, 100	19
2230	Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma. 2005 , 342, 38-46	34

2229	State of the Art Symposium: flow cytometry in the diagnosis of lymphoproliferative disorders by fine-needle aspiration. 2005 , 105, 443-51	54
2228	The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. 2006 , 108, 10-20	22
2227	Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. 2005 , 206, 123-34	117
2226	BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. 2005 , 207, 243-9	584
2225	Protein expression pattern distinguishes different lymphoid neoplasms. 2005 , 5, 4274-86	31
2224	Small Cell Tumors, Lymphomas, and Sertoli Cell and Leydig Cell Tumors of the Bladder, Prostate, and Testis. 2005 , 309-331	1
2223	Technologies for systematic analysis of eukaryotic transcriptomes. 2005 ,	
2222	A 61-year-old man with dyspepsia and weight loss. 2005 , 2, e154	
2221	Best Practice No 185. Cytological and molecular diagnosis of lymphoma. 2005 , 58, 561-7	27
2220	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. 2005 , 46, 693-701	45
2219	Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. 2005 , 11, 4415-29	83
2218	State-of-the-art therapeutics: diffuse large B-cell lymphoma. 2005 , 23, 6387-93	149
2217	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. 2005 , 4, 1867-79	72
2216	Tissue microarrays: bridging the gap between research and the clinic. 2005 , 2, 325-36	50
2215	Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. 2005 , 23, 8012-7	37
2214	Targeting histones and proteasomes: new strategies for the treatment of lymphoma. 2005 , 23, 6429-36	29
2213	Molecular pathogenesis of diffuse large B-cell lymphoma. 2005 , 23, 6351-7	120
2212	Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. 2005 , 23, 7060-8	68

2211	Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma. 2005 , 5, 397-408		1
2210	Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. 2005 , 23, 5044-51		150
2209	Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation. 2005 , 123, 104-12		26
2208	Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. 2005 , 23, 8003-11		51
2207	Inhibition of caspase 9 and not caspase 8 mediated apoptosis may determine clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. 2005 , 4, 526-8		8
2206	Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. 2005 , 26, 151		
2205	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. 2005 , 433, 278-85		418
2204	Monoclonal antibody therapy of leukaemias and lymphomas. 2005 , 5, 1225-43		8
2203	The biology of human lymphoid malignancies revealed by gene expression profiling. 2005 , 87, 163-208		174
2202	Helicobacter pylori and MALT lymphoma. 2005 , 128, 1579-605		131
2201	Management of Diffuse Large B-Cell Lymphoma in Young Patients. 2005 , 4, 349-357		3
2200	Histopathology Reporting. 2006 ,		
2199	B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. 2006 , 47, 495-501		20
2198	Standard treatment of advanced-stage diffuse large B-cell lymphoma. 2006 , 43, 213-20		19
2197	Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. <i>Blood</i> , 2006 , 107, 4047-52	2.2	135
2196	Lymphomes B diffus ^ grandes cellules : de la morphologie ^ la biologie. 2006 , 26, 28-32		0
2195	Treatment of non-Hodgkin's lymphoma: a look over the past decade. 2006 , 7 Suppl 1, S7-13		27
2194	Treatment of diffuse large B-cell lymphoma: a risk-based approach. 2006 , 7 Suppl 1, S14-9		3

2193	Pathology of B-cell non-Hodgkin's lymphomas and multiple myeloma. 2006 , 131, 1-48		1
2192	Underlying mechanisms of hematologic malignancies revealed by gene expression profiling. 2006 , 3, 507-514		3
2191	Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. 2006 , 60, 663-72		39
2190	CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169-monocyte-derived cells in diffuse large B-cell lymphomas. 2006 , 37, 68-77		41
2189	High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. 2006 , 37, 742-8		14
2188	Estratificaçã de risco em linfoma difuso de grandes células B. 2006 , 28, 296		
2187	Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. 2006 , 21, 397-405		27
2186	Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma. 2006 , 47, 2750-6		40
2185	Classification and Histopathology of the Lymphomas. 2006 , 2-38		4
2184	Aggressive Non-Hodgkin's Lymphomas. 2006 ,		
2183	Is it time to stop treating subsets of DLBCL with R-CHOP?. <i>Blood</i> , 2006 , 107, 4197-4198	2.2	3
2182	A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <i>Blood</i> , 2006 , 107, 190-6	2.2	280
2181	Transmembrane adaptor molecules: a new category of lymphoid-cell markers. <i>Blood</i> , 2006 , 107, 213-21	2.2	35
2180	Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. <i>Blood</i> , 2006 , 107, 2477-85	2.2	72
2179	Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. <i>Blood</i> , 2006 , 107, 4090-100	2.2	186
2178	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006 , 107, 4207-13	2.2	227
2177	High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. <i>Blood</i> , 2006 , 108, 2373-83	2.2	52
2176	Subtype preference of the BCL6397G/C polymorphism in germinal-center and non-germinal-center subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2006 , 108, 3623-4	2.2	2

2175	Primary cutaneous marginal zone B-cell lymphoma. 2006 , 125 Suppl, S38-49	7
2174	Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. 2006 , 30, 1604-12	52
2173	Update in HIV lymphoma. 2006 , 18, 449-55	17
2172	B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution. 2006 , 82, 1013-23	13
2171	Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics. 2006 , 1152-1170	
2170	Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. 2006 , 208, 714-23	184
2169	Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas. 2006 , 209, 360-8	27
2168	Jaw1/LRMP, a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. 2006 , 209, 454-63	29
2167	Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. 2006 , 210, 163-71	36
2166	Lymphomes: De la Biologie ^ la Clinique. 2006 , 2006, 17-19	
2165	Présentation hématoologique des lymphomes A cellules B matures (Ganglionnaires et extra-ganglionnaires). 2006 , 2006, 61-72	1
2164	Primary cutaneous B-cell lymphomas: then and now. 2006 , 33 Suppl 1, 1-5	5
2163	Histological variety of floral variant of follicular lymphoma. 2006 , 114, 626-32	13
2162	Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. 2006 , 134, 283-93	14
2161	Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. 2006 , 135, 33-42	33
2160	Clinico-pathological characteristics of p63 expression in B-cell lymphoma. 2006 , 97, 1050-5	32
2159	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. 2006 , 48, 529-35	14
2158	Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice?. 2006 , 86, 742-7	16

2157	AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. 2006 , 19, 438-46	17
2156	A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. 2006 , 19, 299-306	39
2155	Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. 2006 , 19, 963-73	8
2154	Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. 2006 , 19, 1270-6	33
2153	Primary testicular diffuse large B-cell lymphoma belongs to the nongermlinal center B-cell-like subgroup: A study of 18 cases. 2006 , 19, 1521-7	75
2152	Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. 2006 , 20, 1300-3	60
2151	Novel Ig V gene features of t(14;18) and t(3;14) de novo diffuse large B-cell lymphoma displaying germinal center-B cell like and non-germlinal center-B cell like markers. 2006 , 20, 2070-4	7
2150	Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. 2006 , 30, 859-67	24
2149	Classifications moléculaires des lymphomes par analyses d'expression génique à haut débit. 2006 , 8, 314-321	
2148	Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. 2006 , 85, 597-603	24
2147	Gene arrays in lymphoma: Where will they fit in?. 2006 , 1, 129-36	3
2146	Clinical and molecular prognostic factors in follicular lymphoma. 2006 , 8, 359-67	2
2145	Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. 2006 , 76, 465-72	24
2144	Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. 2006 , 54, 3774-81	60
2143	t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. 2006 , 45, 164-8	46
2142	Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. 2006 , 106, 247-57	19
2141	D Cyclins in CD5+ B-Cell Lymphoproliferative Disorders. 2006 , 125, 241-250	23
2140	Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. 2006 , 12, 1152-6	101

2139	Optimal use of prognostic factors in non-Hodgkin lymphoma. 2006 , 2006, 295-302	31
2138	Improved clonality assessment in germinal centre/post-germinal centre non-Hodgkin's lymphomas with high rates of somatic hypermutation. 2007 , 60, 524-8	18
2137	Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. 2006 , 24, 2490-7	121
2136	Immunohistochemical Analysis Identifies Two Cyclin D1+ Subsets of Plasma Cell Myeloma, Each Associated With Favorable Survival. 2006 , 125, 615-624	43
2135	A new description of cellular quiescence. 2006 , 4, e83	339
2134	Large B-cell lymphoma masquerading as acute leukemia. 2006 , 24, 1950-1	5
2133	Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. 2006 , 14, 43-8	21
2132	Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. 2006 , 12, 2125-32	38
2131	Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 2006 , 17, 1434-40	74
2130	Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. 2007 , 60, 167-72	36
2129	Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. 2006 , 66, 3550-7	26
2128	Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. 2006 , 177, 6930-9	110
2127	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. 2006 , 203, 311-7	293
2126	Composite Recurrent Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. 2006 , 126, 222-229	28
2125	Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 2006 , 24, 2472-9	295
2124	Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. 2006 , 17 Suppl 4, iv37-9	9
2123	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. 2006 , 24, 961-8	238
2122	Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. 2006 , 24, 4135-42	131

2121	Significance of the "tissue microarray" technique in diagnosis and prognosis of B non Hodgkin-s lymphomas. 2006 , 25, 317-323	
2120	Involvement of the appendix and palate by pleomorphic variant mantle cell lymphoma. 2006 , 47, 1704-7	11
2119	Prognostic biomarkers in diffuse large B-cell lymphoma. 2006 , 24, 995-1007	209
2118	Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. <i>Blood</i> , 2006 , 107, 265-76.2	1153
2117	Use of bortezomib in B-cell non-Hodgkin's lymphoma. 2006 , 6, 983-91	8
2116	HIV infection and lymphoma. 2007 , 60, 1365-72	178
2115	Nodal aggressive B-cell lymphomas: a diagnostic approach. 2007 , 60, 1076-85	5
2114	FOXP1: a potential therapeutic target in cancer. 2007 , 11, 955-65	117
2113	Clinicopathologic correlations of stage IE/IIe primary thyroid diffuse large B-cell lymphoma. 2007 , 18, 1203-8	34
2112	The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. 2007 , 7, 1749-62	7
2111	Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. 2007 , 18, 931-9	39
2110	Bcl-6 and c-Myc are rarely co-expressed in adult diffuse large B-cell lymphoma. 2007 , 48, 1510-3	6
2109	The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. 2007 , 92, 1335-42	181
2108	Modern Hematology. 2007 ,	15
2107	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. 2007 , 48, 1102-9	58
2106	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. 2007 , 48, 542-6	38
2105	CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. 2007 , 48, 1774-9	15
2104	A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. 2007 , 66, 1627-32	68

2103	Construction and validation of a bone marrow tissue microarray. 2007 , 60, 57-61		22
2102	Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. 2007 , 25, 1581-7		215
2101	Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma. 2007 , 13, 7012-21		19
2100	Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. 2007 , 127, 47-54		33
2099	A comprehensive antibody panel for immunohistochemical analysis of formalin-fixed, paraffin-embedded hematopoietic neoplasms of mice: analysis of mouse specific and human antibodies cross-reactive with murine tissue. 2007 , 35, 366-75		38
2098	Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. 2007 , 25, 805-12		241
2097	Selection of vimentin-specific antibodies from the HuCAL phage display library by subtractive panning on formalin-fixed, paraffin-embedded tissue. 2007 , 388, 651-8		14
2096	Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20. 2007 , 44, 875-84		85
2095	Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. 2007 , 128, 558-64		78
2094	Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. 2007 , 13, 2226-35		135
2093	Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. 2007 , 92, 176-83		14
2092	Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival. 2007 , 3, 117693510700300		36
2091	Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 339-44	2.2	39
2090	MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. 2007 , 92, 267-8		45
2089	Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. <i>Blood</i> , 2007 , 109, 478-85	2.2	323
2088	Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. <i>Blood</i> , 2007 , 109, 331-8	2.2	117
2087	MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. <i>Blood</i> , 2007 , 109, 3500-4	2.2	59
2086	IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. <i>Blood</i> , 2007 , 109, 3060-8.2		61

2085	The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. <i>Blood</i> , 2007 , 109, 1636-42	2.2	126
2084	CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. <i>Blood</i> , 2007 , 109, 3076-9	2.2	115
2083	Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. <i>Blood</i> , 2007 , 109, 4930-5	2.2	235
2082	How I treat patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 29-36	2.2	112
2081	A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. 2007 , 92, 1343-50		32
2080	High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. 2007 , 92, 1297-301		77
2079	New transcription factors in diagnostic hematopathology. 2007 , 14, 25-35		16
2078	IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. 2007 , 31, 1605-14		176
2077	New treatment concepts in diffuse large B-cell lymphomas (DLBL): chemotherapy and biological therapy. 2007 , 2, 149-62		4
2076	Lymphomes diffus ^ grandes cellules B. 2007 , 2, 1-14		2
2075	The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. 2007 , 55, 73-83		62
2074	Primary central nervous system lymphoma: biological aspects and controversies in management. 2007 , 43, 1141-52		48
2073	High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. 2007 , 256, 196-206		45
2072	New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. 2007 , 56, 588-97		47
2071	Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. 2007 , 170, 1362-9		70
2070	Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. 2007 , 48, 2221-32		48
2069	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. 2007 , 21, 2332-43		169
2068	MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas. 2007 , 138, 479-86		24

2067	Innovations in immunohistochemistry for the haematopathologist. 2007 , 27, 33-36		2
2066	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 972-8	2.2	245
2065	Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile. 2007 , 48, 892-6		10
2064	Primary salivary gland lymphoma among Japanese: A clinicopathological study of 30 cases. 2007 , 48, 1793-8		40
2063	Non-germinal cell phenotype and bcl-2 expression in primary adrenal diffuse large B-cell lymphoma. 2007 , 48, 2244-6		6
2062	Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. 2007 , 48, 957-63		11
2061	Biologic predictors in follicular lymphoma: importance of markers of immune response. 2007 , 48, 2403-11		40
2060	Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma. 2007 , 48, 1038-41		4
2059	[DNA microarray technology: principles and applications to the study of neurological disorders]. 2007 , 163, 409-20		3
2058	Lymphoma in older patients. 2007 , 25, 1916-23		99
2057	Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors: pilot study. 2007 , 2, 9		6
2056	Gene expression profiling in diffuse large B-cell lymphoma. 2007 , 48, 669-82		6
2055	MicroRNA expression in lymphoma. 2007 , 7, 1363-74		41
2054	Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. 2007 , 92, 778-83		19
2053	Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. 2007 , 2, 11727190700200		4
2052	Intravascular large B-cell lymphoma: the heterogeneous clinical manifestations of its classical and hemophagocytosis-related forms. 2007 , 92, 434-6		17
2051	Introduction to the Diagnosis of Cancer. 2007 ,		
2050	Diffuse large B-cell lymphoma in the young in Japan: a study by the Osaka Lymphoma Study Group. 2007 , 82, 893-7		19

2049	MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. 2007 , 121, 1156-61	328
2048	Establishment of a human herpes virus-8-negative malignant effusion lymphoma cell line (STR-428) carrying concurrent translocations of BCL2 and c-MYC genes. 2007 , 31, 1285-92	10
2047	The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. 2007 , 31, 1579-83	42
2046	Expression of transmembrane adaptor protein PAG/Cbp in diffuse large B-cell lymphoma: immunohistochemical study of 73 cases. 2007 , 203, 193-8	5
2045	Predictive medicine: incipient reality or fata morgana?. 2007 , 212, 353-5	5
2044	Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma. 2007 , 213, 429-40	15
2043	P051 Immunohistochemical expression patterns of germinal center and activation B-cell markers do not correlate with prognosis in diffuse large B-cell lymphoma treated with R-CHOP. 2007 , 31, S87-S88	
2042	P053 Prognostic and predictive significance of CD10 expression in diffuse large B cell lymphoma. 2007 , 31, S88-S89	
2041	Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. 2007 , 21, 37-43	86
2040	Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. 2007 , 21, 515-23	116
2039	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). 2007 , 21, 1802-11	55
2038	Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. 2007 , 21, 2563-6	36
2037	PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. 2007 , 20, 326-30	18
2036	Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. 2007 , 29, 229-60	21
2035	Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. 2007 , 51, 70-9	33
2034	Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study. 2007 , 51, 697-703	27
2033	Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. 2007 , 136, 38-47	38
2032	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. 2007 , 136, 286-93	124

2031	Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. 2007 , 138, 68-71	58
2030	Somatically mutated immunoglobulin IGHV@ genes without intraclonal heterogeneity indicate a postgerminal centre origin of primary intraocular diffuse large B-cell lymphomas. 2007 , 138, 749-55	24
2029	Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. 2007 , 98, 44-9	32
2028	Diagnostic and prognostic significance of gene expression profiling in lymphomas. 2007 , 115, 1135-46	21
2027	Prediction potential of candidate biomarker sets identified and validated on gene expression data from multiple datasets. 2007 , 8, 415	20
2026	Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering. 2007 , 8, 332	7
2025	Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas. 2007 , 78, 283-9	11
2024	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. 2007 , 79, 146-9	28
2023	Neural cell adhesion molecule (CD56)-positive B-cell lymphoma. 2007 , 79, 166-9	16
2022	Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. 2007 , 79, 501-7	43
2021	Diffuse large B-cell lymphoma. 2007 , 17, 169-75	29
2020	Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma. 2007 , 2, 488-498	2
2019	Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma. 2007 , 85, 41-8	8
2018	[Classification and pathogenesis of malignant lymphomas]. 2007 , 48, 351-61	5
2017	Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. 2007 , 86, 557-64	21
2016	Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. 2007 , 86, 887-95	19
2015	[Intravascular lymphoma causing acute abdomen]. 2007 , 28, 51-4	4
2014	Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. 2007 , 450, 493-502	39

2013	Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. 2007 , 2, 235-41	4
2012	Update on HIV lymphoma. 2007 , 9, 384-90	7
2011	A case of primary hepatic non-Hodgkin's lymphoma with chronic hepatitis C. 2008 , 41, 171-4	3
2010	Primary splenic diffuse large B-cell lymphoma manifesting in red pulp. 2008 , 453, 501-9	29
2009	Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. 2008 , 216, 209-17	89
2008	S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. 2008 , 216, 483-94	19
2007	Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. 2008 , 51, 369-74	72
2006	Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. 2008 , 112, 151-6	62
2005	Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. 2008 , 26, 199-211	74
2004	Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes. 2008 , 32, 1176-82	6
2003	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. 2008 , 32, 1628-32	1
2002	Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. 2008 , 32, 1837-41	24
2001	Molecular diagnostics in haematopathology. 2008 , 14, 223-235	3
2000	Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. 2008 , 22, 1755-66	53
1999	DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. 2008 , 22, 1035-43	78
1998	The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. 2008 , 22, 1917-24	87
1997	Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). 2008 , 22, 2226-9	144
1996	MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. 2008 , 22, 1095-105	127

1995	Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. 2008 , 21, 653-9	17
1994	FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. 2008 , 21, 902-11	61
1993	Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation. 2008 , 21, 282-96	8
1992	Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. 2008 , 42, 93-8	11
1991	Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. 2008 , 99, 1760-8	35
1990	Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. 2008 , 142, 329-47	69
1989	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. 2008 , 141, 69-72	18
1988	Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. 2008 , 142, 166-78	12
1987	Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. 2008 , 142, 404-12	25
1986	Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression. 2008 , 142, 562-70	11
1985	MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 2008 , 142, 732-44	146
1984	Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas. 2008 , 52, 578-84	4
1983	Diffuse large B-cell lymphoma showing an interfollicular pattern of proliferation: a study of the Osaka Lymphoma Study Group. 2008 , 52, 731-7	8
1982	MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. 2008 , 53, 205-17	97
1981	PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation. 2008 , 53, 278-87	28
1980	Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. 2008 , 53, 441-9	21
1979	Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma. 2008 , 53, 432-40	34
1978	Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. 2008 , 58, 529-32	58

1977	Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia. 2008 , 58, 572-9		13
1976	Evaluation of intra- and interobserver agreement and its clinical significance for scoring bcl-2 immunohistochemical expression in diffuse large B-cell lymphoma. 2008 , 58, 596-600		10
1975	MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?. 2008 , 12, 1432-44		48
1974	A clinicopathological study of 13 cases of intravascular lymphoma: experience in a single institution over a 9-yr period. 2008 , 80, 236-44		46
1973	Tissue microarrays in clinical oncology. 2008 , 18, 89-97		92
1972	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. 2008 , 49, 2048-58		23
1971	Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. 2008 , 39, 875-84		19
1970	Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. 2008 , 39, 885-94		17
1969	Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. 2008 , 39, 1323-30		23
1968	Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. 2008 , 14, 108-11		10
1967	Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. 2008 , 14, 259-67		35
1966	Flow cytometric immunophenotyping for hematologic neoplasms. <i>Blood</i> , 2008 , 111, 3941-67	2.2	424
1965	Prognostic systems for lymphomas. 2008 , 22, 839-61, viii		12
1964	Diffuse large B-cell lymphoma. 2008 , 22, 941-52, ix		94
1963	Molecular biology and genetics of lymphomas. 2008 , 22, 807-23, vii		29
1962	Overview of lymphoma diagnosis and management. 2008 , 46, 175-98, vii		69
1961	MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia. 2008 , 49, 273-80		6
1960	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008 , 112, 2248-60	2.2	165

1959	Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. 2008 , 49, 247-56	78
1958	Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. 2008 , 8, 1651-8	20
1957	Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas. 2008 , 49, 1717-23	18
1956	Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene. 2008 , 129, 723-6	21
1955	Molecular pathology of intraocular lymphomas. 2008 , 3, 543-551	1
1954	Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. 2008 , 26, 2717-24	228
1953	Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome. 2008 , 130, 957-62	4
1952	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. 2008 , 19, 560-5	4
1951	Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls. 2008 , 25, 528-40	12
1950	CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. 2008 , 19, 1921-6	65
1949	Detecting hierarchical structure in molecular characteristics of disease using transitive approximations of directed graphs. 2008 , 24, 995-1001	7
1948	Bcl-B expression in human epithelial and nonepithelial malignancies. 2008 , 14, 3011-21	45
1947	A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. 2008 , 129, 630-8	39
1946	p37Ink1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesis. 2008 , 68, 8705-14	17
1945	Current treatment approaches for diffuse large B-cell lymphoma. 2008 , 49, 663-76	18
1944	The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations. 2008 , 130, 193-201	15
1943	Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. 2008 , 14, 3002-10	35
1942	LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. 2008 , 26, 447-54	143

1941	Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. 2008 , 5, 316-23		6
1940	De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. 2008 , 93, 1195-202		102
1939	The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients. 2008 , 49, 113-21		14
1938	Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience. 2008 , 49, 1321-8		19
1937	Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. 2008 , 49, 1345-51		18
1936	Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. 2008 , 4, 199-210		2
1935	Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. 2008 , 19, 1774-86		52
1934	Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. 2008 , 26, 4587-94		253
1933	Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. 2008 , 49, 1501-9		28
1932	Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens. 2008 , 16, 164-70		5
1931	Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. <i>Blood</i> , 2008 , 111, 369-75	2.2	34
1930	Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. <i>Blood</i> , 2008 , 111, 1515-23	2.2	241
1929	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. <i>Blood</i> , 2008 , 111, 351-8	2.2	63
1928	Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. <i>Blood</i> , 2008 , 111, 2816-24	2.2	75
1927	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008 , 112, 3088-98	2.2	138
1926	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , 2008 , 111, 5509-14	2.2	80
1925	[Malignant lymphoma: diagnostic approach. 1. Pathological diagnosis]. 2008 , 97, 1537-45		0
1924	[Malignant lymphoma. Physiopathology and therapy. 3. Diffuse large B-cell lymphoma]. 2008 , 97, 1588-94		

1923	Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. 2008 , 93, 193-200	326
1922	Testicular lymphoma: an update for clinicians. 2008 , 336, 336-41	20
1921	SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. 2008 , 32, 1523-31	111
1920	Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. 2008 , 32, 113-22	47
1919	Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. 2008 , 32, 1299-309	136
1918	Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker. 2008 , 32, 1190-200	34
1917	Exames laboratoriais complementares indicados no apoio ao diagnóstico do linfoma difuso de grandes células B (LDGCB). 2008 , 33,	
1916	TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. 2008 , 40, 441-9	18
1915	Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. 2008 , 49, 625-35	7
1914	Lymphoid Tumors of the GI Tract, Hepatobiliary Tract, and Pancreas. 2009 , 701-732	2
1913	[Prognostic factors in Hodgkin and non-Hodgkin lymphomas]. 2009 , 96, 461-73	1
1912	Physiopathologie des lymphomes diffus ~grandes cellules B. 2009 , 15, 214-222	
1911	Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). 2009 , 62, 128-38	79
1910	Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. 2009 , 50, 54-61	17
1909	Application of Biostatistics and Bioinformatics Tools to Identify Putative Transcription Factor-Gene Regulatory Network of Ankylosing Spondylitis and Sarcoidosis. 2009 , 38, 3326-3338	4
1908	Early detection of patients with poor risk diffuse large B-cell lymphoma. 2009 , 50, 1744-7	17
1907	Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. 2009 , 50, 1301-7	8
1906	Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. 2009 , 27, 5039-48	73

1905	p63 protein expression in high risk diffuse large B-cell lymphoma. 2009 , 62, 77-9	23
1904	Rituximab and chemotherapy in diffuse large B-cell lymphoma. 2009 , 9, 719-26	9
1903	FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. 2009 , 26, 156-62	22
1902	Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry. 2009 , 121, 196-201	13
1901	Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). 2009 , 131, 339-46	11
1900	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. 2009 , 35, 961-71	11
1899	Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. 2009 , 14, 84-9	19
1898	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. 2009 , 50, 1964-8	2
1897	High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. 2009 , 50, 1625-31	11
1896	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. 2009 , 94, 1569-80	35
1895	Thymidylate synthase polymorphism relevant for survival in patients with diffuse large B-cell lymphoma?. 2009 , 50, 1723-5	
1894	Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. 2009 , 27, 5573-9	100
1893	Hematology: germinal center or nongerminal center DLBCL?. 2009 , 6, 188-90	5
1892	Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. 2009 , 20, 526-33	43
1891	B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP. 2009 , 40, 79-86	
1890	Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma. 2009 , 5, 254-62	5
1889	Complexity made simple in diffuse large B-cell lymphoma. 2009 , 15, 5291-3	6
1888	Lymph Nodes. 2009 , 1431-1511	

1887	Pathophysiology of retinal lymphoma. 2009 , 17, 227-37	65
1886	Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. 2009 , 62, 820-4	36
1885	BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. 2009 , 62, 903-7	18
1884	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. 2009 , 15, 4415-22	155
1883	Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma. 2009 , 59, 431-7	20
1882	Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. 2009 , 13, 1248-60	132
1881	Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. 2009 , 82, 364-72	28
1880	Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomas. 2009 , 37, 1259-65	3
1879	Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma. 2009 , 194, 48-52	2
1878	Hypothesis: sarcoidosis is a STAT1-mediated disease. 2009 , 132, 174-83	55
1877	Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. 2009 , 84, 133-9	68
1876	Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. 2009 , 84, 803-8	36
1875	Richter syndrome: molecular insights and clinical perspectives. 2009 , 27, 1-10	95
1874	The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. 2010 , 28, 27-32	24
1873	Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. 2009 , 115, 4980-9	20
1872	Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. 2009 , 1, 288-95	174
1871	Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. 2009 , 455, 285-93	8
1870	Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas. 2009 , 455, 323-36	2

1869	Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma. 2009 , 8, 585-591	
1868	Intravascular large B-cell lymphoma with involvement of the abdominal subcutis: a case report and literature review. 2009 , 89, 348-351	3
1867	Kidney-limited intravascular large B cell lymphoma: a distinct variant of IVLBCL?. 2009 , 89, 533-537	20
1866	Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. 2009 , 89, 600-10	33
1865	Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. 2009 , 89, 673-8	2
1864	Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. 2009 , 90, 74-80	22
1863	Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. 2009 , 4, 218-24	22
1862	Antilymphoma therapy with a Bcl-6 inhibitor. 2009 , 4, 183-4	
1861	Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. 2009 , 2, 20-6	18
1860	Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas. 2009 , 2, 83-7	14
1859	A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score. 2009 , 2, 187-94	6
1858	Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immune-reactivity to malignancy. 2009 , 69, 387-400	17
1857	Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. 2009 , 54, 221-32	20
1856	Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. 2009 , 54, 688-98	97
1855	Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype. 2009 , 100, 42-6	15
1854	Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. 2009 , 100, 233-7	38
1853	Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. 2009 , 100, 920-6	122
1852	Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. 2009 , 100, 1255-60	31

1851	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. 2009 , 100, 1842-7	77
1850	Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. 2009 , 144, 24-40	81
1849	Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. 2009 , 146, 396-407	25
1848	BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution. 2009 , 146, 683-4	9
1847	Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. 2009 , 23, 777-83	185
1846	Toward a systems biology approach to investigate cellular networks in normal and malignant B cells. 2009 , 23, 1219-25	4
1845	Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. 2009 , 22, 547-55	67
1844	Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. 2009 , 22, 1507-17	14
1843	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. 2009 , 22, 1094-101	87
1842	Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. 2009 , 22, 1210-7	51
1841	Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. 2009 , 22, 1312-20	78
1840	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. 2009 , 459, 717-21	826
1839	Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. 2009 , 43, 323-5	6
1838	Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. 2010 , 30, 232-40	40
1837	Intravascular lymphoma presenting with neurological signs but diagnosed by prostate biopsy: suspicion as a key to early diagnosis. 2009 , 16, e39-41	8
1836	TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. 2009 , 33, 60-6	24
1835	Aberrant somatic hypermutations in thyroid lymphomas. 2009 , 33, 649-54	10
1834	Tumors that look for their springtime in APRIL. 2009 , 72, 91-7	23

1833	Defining the molecular target of an antibody derived from nuclear extract of Jurkat cells using protein arrays. 2009 , 395, 119-24		4
1832	Gene expression profiling in lymphoma diagnosis and management. 2009 , 22, 191-210		27
1831	Primary cardiac lymphoma: molecular cytogenetic characterization of a rare entity. 2009 , 18, 92-9		5
1830	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. 2009 , 40, 645-52		87
1829	Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. 2009 , 40, 565-71		20
1828	Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongermlinal center B-cell phenotype. 2009 , 40, 653-61		83
1827	IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. 2009 , 40, 1699-705		28
1826	Les lymphomes agressifs. 2009 , 33, 478-481		2
1825	The role of biomarkers in the management of patients with lymphoma: promise versus reality. 2009 , 9, 121-3		1
1824	CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. 2009 , 9, 133-7		17
1823	Management of immunocompetent patients with primary central nervous system lymphoma. 2009 , 9, 353-64		13
1822	ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. 2009 , 2, 11		65
1821	Hematopoietic Lesions. 2009 , 933-974		3
1820	Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. 2009 , 50, 1666-75		18
1819	Molecular Biology. 2009 , 85-120		
1818	Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. 2009 , 15, 4453-9		165
1817	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009 , 114, 3533-7	2.2	484
1816	Patterns of microRNA expression characterize stages of human B-cell differentiation. <i>Blood</i> , 2009 , 113, 4586-94	2.2	193

1815	pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. 2009 , 50, 1276-82		14
1814	Primary intestinal diffuse large B-cell lymphoma presenting as multiple lymphomatous polyposis. 2009 , 50, 1219-22		2
1813	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. 2009 , 15, 5494-502		507
1812	Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. 2009 , 50, 571-81		7
1811	Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis. 2009 , 50, 410-8		3
1810	MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. 2009 , 62, 715-23		18
1809	Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications. 2009 , 174, 2337-46		31
1808	Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. 2009 , 175, 2609-17		20
1807	Presentation and management of intravascular large B-cell lymphoma. 2009 , 10, 895-902		210
1806	Diffuse large B-cell lymphomas and burkitt lymphoma. 2009 , 23, 791-827		41
1805	Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature. 2009 , 33, 1463-9		28
1804	Diffuse aggressive B-cell lymphomas. 2009 , 16, 216-35		16
1803	Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. 2009 , 33, 1815-22		25
1802	[Pathology of malignant lymphoma]. 2009 , 112, 465-73		1
1801	Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. 2009 , 94, 935-43		169
1800	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2009 , 113, 6069-76	2.2	422
1799	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. <i>Blood</i> , 2009 , 113, 3773-80	2.2	106
1798	Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. <i>Blood</i> , 2009 , 113, 3754-64	2.2	213

1797	Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. <i>Blood</i> , 2009 , 113, 6681-90 ^{2,2}	64
1796	Micro-classifying diffuse large B-cell lymphomas. <i>Blood</i> , 2009 , 113, 6506-7	2.2 1
1795	Prognostic subgroup distribution in diffuse large B-cell lymphoma of the upper aerodigestive tract. 2009 , 41, 133-9	6
1794	NCCN task force report: molecular markers in leukemias and lymphomas. 2009 , 7 Suppl 4, S1-34, quiz S35-6	8
1793	Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. 2009 , 94, 1020-3	17
1792	Classification histopathologique, immunologique, cytogénétique et moléculaire des lymphomes non hodgkiniens. 2009 , 4, 1-23	2
1791	Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. 2010 , 18, 109-12	6
1790	MUM1/IRF4: A Review. 2010 , 18, 301-10	58
1789	The basis and rational use of molecular genetic testing in mature B-cell lymphomas. 2010 , 17, 333-58	7
1788	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. 2010 , 34, 327-40	290
1787	Epstein-Barr virus-associated diffuse large B-cell lymphoma arising on cardiac prostheses. 2010 , 34, 377-84	52
1786	Gall bladder and extrahepatic bile duct lymphomas: clinicopathological observations and biological implications. 2010 , 34, 1277-86	48
1785	BCL6, MUM1, and CD10 expression in mantle cell lymphoma. 2010 , 18, 103-8	42
1784	IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. 2010 , 34, 1043-8	73
1783	NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. 2010 , 8, 288-334	185
1782	Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. 2010 , 95, 1334-41	11
1781	Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders. 2010 , 34, 645-55	13
1780	Genomic analysis of lymphoma: potential for clinical application. 2010 , 8, 353-60	2

1779	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. 2010 , 37, 367-76		19
1778	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. 2010 , 95, 96-101		53
1777	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. <i>Blood</i> , 2010 , 115, 289-95	2.2	145
1776	Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. <i>Blood</i> , 2010 , 116, 4916-25	2.3	148
1775	Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. <i>Blood</i> , 2010 , 116, 5256-67	2.2	76
1774	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , 2010 , 116, e118-27	2.2	167
1773	The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2010 , 115, 3017-24	2.2	156
1772	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. 2010 , 95, 2056-62		20
1771	Profiling the cancer genome. 2010 , 11, 133-59		36
1770	The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. 2010 , 89, 171-7		24
1769	Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy. 2010 , 89, 985-91		15
1768	A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. 2010 , 89, 1107-13		26
1767	[Grayzone lymphoma. Clinical relevance]. 2010 , 31, 42-9		
1766	Surgical pathology of the thymus and mediastinum. 2010 , 16, 143-160		2
1765	Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. 2010 , 4, 181-91		35
1764	Primary cutaneous diffuse large B cell lymphoma relapsed solely as a huge lung tumor mimicking a primary pulmonary lymphoma. 2010 , 91, 112-6		2
1763	Loss of promoter methylation contributes to the expression of functionally impaired PRDM14 isoform in diffuse large B-cell lymphoma. 2010 , 92, 439-44		13
1762	Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. 2010 , 98, 341-8		32

1761	Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy. 2010 , 99, 95-101	9
1760	Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases. 2010 , 100, 249-53	7
1759	Improving outcomes for patients with diffuse large B-cell lymphoma. 2010 , 60, 393-408	100
1758	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. 2010 , 10, 321	54
1757	Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association. 2010 , 10, 344	16
1756	Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors. 2010 , 10, 358	25
1755	Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. 2010 , 17, 262-72	135
1754	BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. 2010 , 18, 568-79	222
1753	Constitutive canonical NF- κ B activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. 2010 , 18, 580-9	146
1752	Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. 2010 , 38, 38-45	30
1751	Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. 2010 , 84, 493-8	17
1750	Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. 2010 , 85, 149-57	28
1749	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 2010 , 116, 5667-75	13
1748	Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. 2010 , 116, 5432-9	43
1747	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. 2010 , 28, 62-7	34
1746	Vav-1 expression correlates with NF κ B activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines. 2010 , 28, 142-50	7
1745	Multicentre phase II study of CycLOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. 2010 , 28, 68-74	9
1744	ASH 2009 meeting report Top 10 clinically oriented abstracts in lymphoma. 2010 , 85, 280-283	

1743	Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples. 2010 , 85, 418-25	6
1742	Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group. 2010 , 206, 439-44	8
1741	Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. 2010 , 206, 611-5	21
1740	Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. 2010 , 34, 585-93	13
1739	Diffuse large B-cell lymphoma. 2010 , 16, 69-81	14
1738	Lymphoproliferative disorders in the immunosuppressed. 2010 , 16, 206-215	6
1737	Diagnosis and staging in gastrointestinal lymphoma. 2010 , 24, 3-12	26
1736	Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. 2010 , 101, 1309-13	60
1735	DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. 2010 , 101, 1722-30	65
1734	FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. 2010 , 57, 73-80	37
1733	Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome. 2010 , 57, 785-95	25
1732	High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. 2010 , 149, 560-8	62
1731	Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. 2010 , 149, 569-77	45
1730	Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. 2010 , 150, 229-32	2
1729	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. 2010 , 151, 221-31	45
1728	Late relapse in patients with diffuse large B-cell lymphoma. 2010 , 151, 354-8	18
1727	Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. 2010 , 90, 1346-56	26
1726	CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies. 2010 , 2, 980-92	28

1725	BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas. 2010 , 50, 121-7		8
1724	Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas. 2010 , 29, 47-53		76
1723	Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction. 2010 , 57, 449-54		
1722	Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. 2010 , 28, 2094-100		90
1721	How I treat elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2010 , 116, 5103-10	2.2	108
1720	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. 2010 , 42, 547-52		33
1719	Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. 2010 , 134, 278-81		8
1718	Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. 2010 , 63, 1095-100		12
1717	C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. 2010 , 133, 473-83		15
1716	Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. 2010 , 28, 4740-6		157
1715	Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. 2010 , 21, 140-4		42
1714	Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. 2010 , 21, 2069-2074		39
1713	Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. 2010 , 133, 305-13		28
1712	Determination of apoptosis, proliferation status and O6-methylguanine DNA methyltransferase methylation profiles in different immunophenotypic profiles of diffuse large B-cell lymphoma. 2011 , 28, 15-26		3
1711	Reply to K. Dunleavy et al. 2010 , 28, e261-e262		5
1710	Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. 2010 , 9, 1244-55		34
1709	PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma. 2010 , 51, 1692-8		12
1708	Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. 2010 , 28, 2373-80		405

1707	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010 , 116, e90-8	2.2	179
1706	Diffuse large B-cell lymphoma presenting as pancoast tumor. 2010 , 28, e254-6		3
1705	Upper aerodigestive tract lymphoma in Taiwan. 2010 , 63, 888-93		12
1704	Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2010 , 28, 1017-24		47
1703	Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. 2010 , 51, 2054-62		8
1702	Novel disease targets and management approaches for diffuse large B-cell lymphoma. 2010 , 51 Suppl 1, 1-10		20
1701	Prognostic biomarkers in malignant lymphomas. 2010 , 51 Suppl 1, 11-9		19
1700	Unresolved issues in diffuse large B-cell lymphomas. 2010 , 10, 387-402		4
1699	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. 2010 , 107, 3093-8		32
1698	Comparison of Choi and Hans' algorithms by immunohistochemistry and quantitative reverse transcriptase-PCR - letter. 2010 , 16, 3805-6		1
1697	Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. 2010 , 21, 833-841		22
1696	AIDS-Related Lymphomas. 2010 , 367-385		
1695	Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. 2010 , 51, 2021-30		8
1694	Pathology Quiz Case 1: Diagnosis. 2010 , 136, 842		
1693	Expression and alteration of p16 in diffuse large B cell lymphoma. 2010 , 77, 96-105		3
1692	Serotonin receptor 3A expression in normal and neoplastic B cells. 2010 , 77, 129-35		22
1691	Primary testicular lymphoma: a strictly homogeneous hematological disease?. 2010 , 23, 1261-7		15
1690	CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression. 2010 , 15, 157-61		7

1689	A systematic review on Richter syndrome: what is the published evidence?. 2010 , 51, 415-21	34
1688	Clinicopathologic features of primary lymphoma in soft tissue. 2010 , 51, 2039-46	9
1687	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. 2010 , 51, 2063-9	13
1686	Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. 2010 , 51, 66-72	45
1685	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. 2010 , 95, 1342-9	106
1684	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. 2010 , 21, 1217-1221	17
1683	Cutaneous Richter's syndrome, prognosis, and clinical, histological and immunohistological patterns: report of four cases and review of the literature. 2010 , 220, 226-33	14
1682	Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. 2010 , 23, 235-43	48
1681	Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. 2010 , 23, 686-93	19
1680	[Molecular abnormalities in lymphomas]. 2010 , 97, 1347-64	3
1679	A Practical Approach to the Evaluation of Lymphoid and Plasma Cell Infiltrates in the Lung. 2010 , 3, 129-54	
1678	[Splenic pathology. Case 7. Diffuse large B-cell lymphoma]. 2010 , 30, 233-7	
1677	Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. 2010 , 203, 328-32	17
1676	Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. 2010 , 10, 118-24	11
1675	A decade of progress in lymphoma: advances and continuing challenges. 2010 , 10, 414-23	38
1674	Aggressive B-cell Lymphomas: Diffuse Large B-cell Lymphoma and Burkitt Lymphoma. 2010 , 303-322	1
1673	High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. 2010 , 51, 1260-8	13
1672	CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 2010 , 41, 271-80	25

1671	Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. 2010 , 41, 352-7	104
1670	T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. 2010 , 41, 1238-44	3
1669	Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma. 2010 , 44, 55-61	3
1668	Prognostic significance of pSTAT3 and Survivin expression in diffuse large B-cell lymphoma. 2010 , 3, 7-13	5
1667	Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. 2010 , 177, 1470-9	53
1666	Prognostic factors in follicular lymphoma. 2010 , 28, 2902-13	117
1665	Cancer Gene Profiling. 2010 ,	1
1664	DNA Microarrays in Biological Discovery and Patient Care. 2010 , 73-88	3
1663	Genomics in the Management of Lymphomas. 2010 , 407-420	
1662	Unraveling the interactions between environmental factors and genetic polymorphisms in non-Hodgkin lymphoma risk. 2010 , 10, 403-13	10
1661	CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. 2010 , 51, 1643-8	9
1660	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. 2010 , 51, 1225-32	31
1659	Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. 2010 , 51, 1758-60	13
1658	Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. 2010 , 7, 336-46	101
1657	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. 2010 , 28, 3360-5	440
1656	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. 2010 , 51, 199-212	77
1655	Genetic variation in tumor necrosis factor and risk of diffuse large B-cell lymphoma and follicular lymphoma: differences between subgroups in Swedish patients. 2010 , 51, 1563-6	7
1654	Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. 2011 , 52, 1321-35	75

1653	Prognostication of diffuse large B-cell lymphoma in the rituximab era. 2011 , 52, 360-73		23
1652	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. 2011 , 52, 153-6		4
1651	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011 , 117, 3391-401	2.2	249
1650	Quick Reference Handbook for Surgical Pathologists. 2011 ,		15
1649	BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study. 2011 , 64, 866-9		3
1648	Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients. 2011 , 52, 2356-64		11
1647	Non-Hodgkin's lymphoma: the old and the new. 2011 , 11 Suppl 1, S87-90		12
1646	Biological characterization of nodal versus extranodal presentation of diffuse large B-Cell lymphoma using immunohistochemistry. 2011 , 11, 403-8		8
1645	EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. 2011 , 11, 512-6		52
1644	The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. 2011 , 25, 1869-1876		91
1643	Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. 2011 , 11, 23-32		10
1642	Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling. 2011 , 4, 27		20
1641	Zastosowanie technologii mikromacierzy w onkologii dziecięcej. 2011 , 86, 376-384		
1640	The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. 2011 , 29, 1835-43		94
1639	Hematopathology. 2011 ,		
1638	p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression. 2011 , 179, 1630-7		2
1637	High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. 2011 , 204, 129-37		27
1636	Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. 2011 , 42, 204-13		121

1635	Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2011 , 42, 1459-66	37
1634	High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas. 2011 , 23, 147-53	2
1633	Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma. 2011 , 4, 58-62	1
1632	Molecular pathogenesis of diffuse large B-cell lymphoma. 2011 , 28, 167-77	63
1631	Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. 2011 , 32, 913-20	7
1630	A Study of the Newer Prognostic Markers in Diffuse Large B Cell Lymphomas. 2011 , 67, 41-5	1
1629	[Impact of the pathology in modern medicine]. 2011 , 27, 651-5	4
1628	Lymphomas of the Esophagus, Gastrointestinal Tract, Hepatobiliary Tract, and Pancreas. 2011 , 133-196	
1627	Pediatric mature B-cell non-Hodgkin lymphomas. 395-428	
1626	Current approaches to the treatment of non-Hodgkin's lymphoma. 2011 , 3, e3	1
1625	Lymphoma. 2011 , 419-449	
1624	Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. 2011 , 26, 1556-62	5
1623	BCL2 and MYC dual-hit lymphoma/leukemia. 2011 , 51, 7-12	47
1622	Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. 2011 , 6, e24617	23
1621	Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma. 2011 , 18, 288-92	8
1620	The differential diagnosis between primary cutaneous large B-cell lymphoma and cutaneous follicular lymphoma: prognostic and therapeutic implications. 2011 , 33, 819-26	8
1619	MYC and aggressive B-cell lymphomas. 2011 , 18, 219-28	111
1618	Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?. 2011 , 20, 48-54	1

1617	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 117, 2405-13	2.2	28
1616	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor- κ B-inducing kinase while activating both canonical and alternative nuclear factor- κ B pathways. <i>Blood</i> , 2011 , 117, 200-10	2.2	57
1615	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood</i> , 2011 , 117, 4836-43	2.2	249
1614	Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. <i>Blood</i> , 2011 , 118, 139-47	2.2	222
1613	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 118, 6342-52	2.2	82
1612	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011 , 117, 7070-8	2.2	138
1611	Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. 2011 , 39, 1413-20		18
1610	Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. 2011 , 25, 1183-90		12
1609	Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. 2011 , 96, 558-66		99
1608	Clinicopathological features of malignant lymphoma in Japan: the Miyagi Study. 2011 , 224, 151-60		13
1607	Significance of aldehyde dehydrogenase 1 expression in stromal cells of diffuse large B-cell lymphoma. 2011 , 2, 591-594		5
1606	Development of a Portable Tissue Micro Array Instrument. 2011 , 5,		0
1605	Non-Hodgkin's lymphomas. 2011 , 9, 484-560		47
1604	The role of BCL6 in lymphomas and routes to therapy. 2011 , 152, 3-12		46
1603	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. 2011 , 152, 777-80		14
1602	Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease. 2011 , 153, 236-43		73
1601	Co-infection of human herpesvirus-6 and human herpesvirus-8 in primary cutaneous diffuse large B-cell lymphoma, leg type. 2011 , 155, 514-6		9
1600	Impact of gene expression profiling in lymphoma diagnosis and prognosis. 2011 , 58, 106-27		11

1599	Early phase of Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma of the elderly mimicking EBV-positive reactive follicular hyperplasia. 2011 , 59, 571-5	9
1598	Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. 2011 , 59, 672-8	50
1597	Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. 2011 , 7, 346-50	6
1596	The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on 'EBV-positive DLBCL of the elderly'. 2011 , 119, 309-16	26
1595	Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. 2011 , 25, 153-60	66
1594	The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. 2011 , 25, 681-8	56
1593	The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. 2011 , 25, 1502-9	138
1592	Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). 2011 , 86, 246-55	19
1591	The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas. 2011 , 86, 466-76	5
1590	Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. 2011 , 87, 217-27	23
1589	BCL3 rearrangement, amplification and expression in diffuse large B-cell lymphoma. 2011 , 87, 480-5	7
1588	Personalized treatment of lymphoma: promise and reality. 2011 , 38, 225-35	8
1587	Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. 2011 , 6, 77	145
1586	Clear cell variant of diffuse large B-cell lymphoma: a case report. 2011 , 5, 182	6
1585	Germinal center B-cell-like diffuse large B-cell lymphoma of the duodenum is associated with t(14;18) translocation. 2011 , 61, 742-8	4
1584	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011 , 118, 1350-8	2.2 152
1583	Diagnostic moléculaire des hémopathies lymphoïdes matures. 2011 , 13, 537-541	
1582	A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CycLOBEAP plus rituximab therapy. 2011 , 90, 185-92	8

1581	Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2011 , 90, 409-16	70
1580	FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. 2011 , 90, 701-8	19
1579	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. 2011 , 68, 1135-43	2
1578	Diffuse large B-cell lymphoma of non-germinal center B-cell type of the heart in an immunocompetent woman: an autopsy case. 2011 , 28, 207-10	8
1577	Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. 2011 , 28, 241-8	6
1576	High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. 2011 , 93, 502-508	63
1575	High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma. 2011 , 93, 720-726	10
1574	Spontaneous remission in localized diffuse large B-cell lymphoma. 2011 , 17, 779-84	14
1573	New developments in the pathology of malignant lymphoma: a review of the literature published from November 2010-January 2011. 2011 , 4, 31-43	
1572	Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma. 2011 , 23, 160-4	7
1571	The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. 2011 , 223, 274-82	17
1570	The biological and clinical impact of inhibition of NF- κ B-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). 2011 , 224, 355-66	42
1569	Pathologie moléculaire des lymphomes diffus à grandes cellules B : intérêt diagnostique et pronostique pour l'histopathologiste. 2011 , 2011, 57-64	0
1568	EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. 2011 , 86, 663-7	55
1567	Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas. 2011 , 50, 715-25	7
1566	Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. 2011 , 117, 5058-66	226
1565	Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas). 2011 , 119, 254-62	10
1564	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. 2011 , 29, 38-41	23

1563	Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma. 2011 , 29, 185-9	17
1562	A fatal case of hemoperitoneum after ultrasound-guided liver biopsy in a patient with intravascular large B-cell lymphoma. 2011 , 13, 191-5	5
1561	Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. 2011 , 35, 438-43	20
1560	Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. 2011 , 2, 402	36
1559	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. 2011 , 29, 4079-87	207
1558	Quantitative image analysis in the assessment of diffuse large B-cell lymphoma. 2011 , 24, 1598-605	13
1557	Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma. 2011 , 126, 79-86	4
1556	Predictive markers and driving factors behind Richter syndrome development. 2011 , 11, 433-42	12
1555	Notice of Retraction: Primary Breast Diffuse Large B-Cell Lymphomas. 2011 ,	
1554	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. 2011 , 52, 1495-503	17
1553	Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. 2011 , 38, 1891-7	28
1552	The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. 2011 , 135, 54-61	60
1551	Relapsed diffuse large B-cell lymphoma: clinical utility of cell of origin. 2011 , 29, 4065-6	5
1550	Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. 2011 , 17, 4245-53	42
1549	Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma. 2011 , 23, 227-31	1
1548	MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. 2011 , 17, 4125-35	110
1547	Diffuse large B-cell lymphoma, not otherwise specified, associated with coinfection of human herpesvirus 6 and 8. 2011 , 29, e636-7	3
1546	A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. 2011 , 17, 1440-51	51

1545	Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?. 2011 , 19, 417-24	1
1544	Pitfalls in lymphoma pathology: avoiding errors in diagnosis of lymphoid tissues. 2011 , 64, 466-76	21
1543	The emerging role of lenalidomide in the management of lymphoid malignancies. 2011 , 2, 45-53	5
1542	Micro-RNA Expression and Function in Lymphomas. 2011 , 2011, 347137	29
1541	Clinicopathologic characteristics of CD99-positive diffuse large B-cell lymphoma. 2011 , 125, 167-74	10
1540	Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. 2011 , 2011, 506-14	74
1539	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. 2011 , 29, 200-7	360
1538	Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. 2011 , 52, 458-66	35
1537	Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. 2011 , 29, 1620-6	56
1536	Diffuse large B-cell lymphoma with germinal center B-cell phenotype mimicking primary effusion lymphoma. 2011 , 29, e271-3	3
1535	Relapsed/refractory diffuse large B-cell lymphoma. 2011 , 2011, 498-505	296
1534	Lymphomas of the Nervous System and the Meninges. 2011 , 7-33	2
1533	Diffuse large B-cell lymphoma primary of lung. 2011 , 16, 110-2	35
1532	MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. 2011 , 16, 368-72	11
1531	NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. 2011 , 286, 1675-82	72
1530	Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. 2011 , 17, 3727-32	60
1529	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. 2011 , 17, 7785-95	132
1528	The molecular biology of diffuse large B-cell lymphoma. 2011 , 2, 369-79	10

1527	Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. 2011 , 52, 1681-8	15
1526	Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. 2011 , 56, 436-9	22
1525	Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. 2011 , 52, 1904-12	23
1524	Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. 2011 , 29, 690-7	257
1523	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. 2011 , 17, 4232-44	262
1522	Pediatric follicular lymphoma: a report of the first 3 cases from Taiwan and literature review. 2011 , 28, 661-8	2
1521	Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. 2011 , 13, 1090-8	68
1520	Diffuse large B-cell lymphoma involving the central nervous system. 2011 , 19, 44-50	9
1519	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. 2011 , 52, 2270-5	26
1518	Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. 2012 , 53, 185-94	41
1517	The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma. 2012 , 2012, 195484	7
1516	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 2012 , 30, 3452-9	669
1515	Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma. 2012 , 18, 6122-35	34
1514	Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. 2012 , 209, 291-305	34
1513	Molecular Characteristics of Diffuse Large B-cell Lymphoma, Not Otherwise Specified. 2012 , 17, 41-51	1
1512	The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. 2012 , 35, 126-9	19
1511	Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. 2012 , 23, 1274-1279	25
1510	Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. 2012 , 18, 4702-12	30

1509	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 2012 , 30, 3460-7	494
1508	Concordant and discordant bone marrow involvement in diffuse large B-cell lymphoma: are they understudied phenomena?. 2012 , 30, 336; author reply 336-7	3
1507	Subcutaneous diffuse large B-cell lymphoma with intraocular involvement. 2012 , 8, 757-60	3
1506	The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. 2012 , 25, 1439-45	5
1505	Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. 2012 , 53, 1494-500	18
1504	Back to basics: the complete blood cell count adds to the ability of immunohistochemistry in diffuse large B-cell lymphoma prognosis. 2012 , 53, 2097-8	1
1503	Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. 2012 , 97, 1092-100	35
1502	The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. 2012 , 92, 1574-82	62
1501	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. 2012 , 25, 968-82	140
1500	Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. 2012 , 53, 2175-81	10
1499	Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. 2012 , 53, 34-42	35
1498	Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. 2012 , 2, e67	10
1497	Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. 2012 , 53, 2159-65	42
1496	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. 2012 , 107, 491-500	47
1495	Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. 2012 , 53, 2383-9	22
1494	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. 2012 , 23, 729-735	17
1493	Tumors of the Central Nervous System, Volume 9. 2012 ,	
1492	Clinical and pathological features of B-cell non-Hodgkin lymphomas lacking the surface expression of immunoglobulin light chains. 2012 , 50, 1665-70	6

1491	Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? 2012 , 17, 1562-73	33
1490	Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma. 2012 , 6, 395-405	1
1489	Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. 2012 , 2012, 87-98	15
1488	Molecular profiling of aggressive lymphomas. 2012 , 2012, 464680	3
1487	Lenalidomide in diffuse large B-cell lymphoma. 2012 , 2012, 861060	14
1486	Two-dimensional matrix algorithm using detrended fluctuation analysis to distinguish Burkitt and diffuse large B-cell lymphoma. 2012 , 2012, 947191	5
1485	Advances in the diagnosis and management of lymphoma. 2012 , 29	1
1484	Prognostic Biomarkers and EBV Infection Research in Diffuse Large B-Cell Lymphoma of the Palatine Tonsils. 2012 , 2012, 652682	3
1483	The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. 2012 , 18, 411-20	75
1482	Diffuse large B-cell lymphoma: current strategies and future directions. 2012 , 19, 204-13	84
1481	Biological prognostic markers in diffuse large B-cell lymphoma. 2012 , 19, 214-26	21
1480	Comments on cutaneous lymphomas: since the WHO-2008 classification to present. 2012 , 34, 274-84	4
1479	Leukocytoclastic vasculitis as early manifestation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly. 2012 , 34, 330-4	5
1478	Fibrin-associated large B-cell lymphoma: part of the spectrum of cardiac lymphomas. 2012 , 36, 1527-37	38
1477	Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry. 2012 , 4, e3	9
1476	The WHO Classification of Hematological Malignancies (2008). 2012 , 15-27	
1475	Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup. 2012 , 97, e3; author reply e4	8
1474	Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. <i>Blood</i> , 2012 , 119, 1459-67	2.2 36

1473	How I treat HIV-associated lymphoma. <i>Blood</i> , 2012 , 119, 3245-55	2.2	104
1472	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. <i>Blood</i> , 2012 , 120, 4400-6	2.2	49
1471	Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012 , 120, 3858-60	2.2	42
1470	TP53 mutations and rituximab-CHOP. <i>Blood</i> , 2012 , 120, 3867-9	2.2	1
1469	Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. 2012 , 3, 763-770		43
1468	CNS prophylaxis in diffuse large B-cell lymphoma. 2012 , 379, 1486; author reply 1486-7		
1467	Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. 2012 , 53, 1469-73		20
1466	A spindle cell variant of diffuse large B-cell lymphoma is characterized by T-cell/myofibrohistio-rich stromal alterations: analysis of 10 cases and a review of the literature. 2012 , 89, 302-10		10
1465	Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. 2012 , 159, 441-53		66
1464	High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. 2012 , 89, 395-402		10
1463	Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. 2012 , 103, 1898-904		13
1462	Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder. 2012 , 61, 1183-97		45
1461	Malignant lymphoma of the spleen in Japan: a clinicopathological analysis of 115 cases. 2012 , 62, 577-82		24
1460	B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma. 2012 , 137, 805-14		10
1459	Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. 2012 , 25, 1203-11		18
1458	Pathogenesis and management of primary CNS lymphoma. 2012 , 12, 623-33		18
1457	[Lymphomas and lymphatic leukemias in the bone marrow]. 2012 , 33, 518-27		1
1456	MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. 2012 , 22, 812-24		182

1455	Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. 2012 , 23, 3143-3151		33
1454	Small Round Cell Tumors of Bone. 2012 , 5, 231-56		1
1453	New insights into the diagnosis of lymphomas. 2012 , 23 Suppl 10, x83-8		11
1452	Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. 2012 , 42, 1035-42		16
1451	Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma. 2012 , 53, 1764-8		10
1450	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. 2012 , 97, 758-65		134
1449	Double-hit diffuse large B-cell lymphoma. 2012 , 30, 3439-43		70
1448	Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. 2012 , 14, 223-32		22
1447	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 2012 , 26, 2103-13		251
1446	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012 , 120, 2290-6	2.2	48
1445	Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions. 2012 , 18, 4538-48		9
1444	MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012 , 119, 4619-24	2.2	123
1443	Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. <i>Blood</i> , 2012 , 120, 4609-20	2.2	115
1442	Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases. 2012 , 154, 87-98.e1		31
1441	CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. 2012 , 43, 1344-5		6
1440	Relapses, treatments and new drugs. 2012 , 25, 49-60		9
1439	Diffuse large B cell lymphoma: how can we cure more patients in 2012?. 2012 , 25, 41-7		9
1438	From drug discovery to biomarker-driven clinical trials in lymphoma. 2012 , 9, 643-53		23

1437	MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. 2012 , 1, 141-55	54
1436	Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma. 2012 , 12, 77	6
1435	CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution. 2012 , 10, 84	18
1434	Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). 2012 , 5, 49	58
1433	Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?. 2012 , 61, 1214-8	25
1432	Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. 2012 , 26, 1356-64	83
1431	The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. 2012 , 91, 1731-9	25
1430	Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. 2012 , 181, 1879-88	24
1429	Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. 2012 , 16, 335-43	9
1428	Lymphoid Tumours of the Stomach. 2012 , 241-269	1
1427	Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. 2012 , 29, 2153-8	12
1426	Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). 2012 , 29, 3515-21	10
1425	Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. 2012 , 29, 3352-9	12
1424	Liquid tumors in the elderly. 2012 , 28, 115-52	
1423	Expression of immunohistochemical markers in patients with AIDS-related lymphoma. 2012 , 16, 74-7	5
1422	Molecular Pathology of Malignant Lymphoma. 2012 , 5, 879-902	
1421	CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. 2012 , 91, 1897-906	14
1420	Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. 2012 , 1, 2	25

1419	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. 2012 , 53, 242-6	11
1418	Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. 2012 , 53, 763-9	14
1417	Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL. 2012 , 52, 91-9	7
1416	Expression of immunohistochemical markers in patients with AIDS-related lymphoma. 2012 , 16, 74-77	4
1415	Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?. 2012 , 2012, 410-416	18
1414	Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. 2012 , 2012, 897178	9
1413	Treatment of diffuse large B cell lymphoma. 2012 , 27, 369-77	18
1412	The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. 2013 , 60, 68-73	12
1411	MicroRNA signatures in B-cell lymphomas. 2012 , 2, e57	68
1410	Molecular genetic characterization of lymphoma: application to cytology diagnosis. 2012 , 40, 542-55	20
1409	Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. 2012 , 30, 143-9	23
1408	Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. 2012 , 30, 8-12	5
1407	Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. 2012 , 131, 235-43	28
1406	BCL2 mutations in diffuse large B-cell lymphoma. 2012 , 26, 1383-90	97
1405	Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. 2012 , 87, 865-9	31
1404	Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. 2012 , 118, 4173-83	114
1403	Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. <i>Blood</i> , 2012 , 119, 2844-53	2.2 117
1402	Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. 2012 , 91, 705-714	46

1401	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. 2012 , 250, 523-31	22
1400	Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. 2012 , 60, 313-9	66
1399	Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCL) while other markers for nodal DLCL are not useful. 2012 , 60, 785-92	17
1398	Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group. 2012 , 60, 924-32	10
1397	Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. 2012 , 61, 18-25	18
1396	Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. 2012 , 61, 33-46	27
1395	SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. 2012 , 61, 685-93	37
1394	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. 2012 , 61, 945-54	34
1393	High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. 2012 , 88, 510-7	32
1392	Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience. 2012 , 89, 63-71	78
1391	The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2012 , 36, 413-7	33
1390	The Hans classifier does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients. 2012 , 36, 544-5	8
1389	Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma. 2012 , 191, 108-14	9
1388	Role of activation-induced cytidine deaminase in the progression of follicular lymphoma. 2012 , 103, 415-21	9
1387	Treatment of the elderly patient with diffuse large B cell lymphoma. 2012 , 157, 159-70	30
1386	Topo II α gene alterations correlated with survival in patients with diffuse large B-cell lymphoma. 2012 , 42, 310-20	8
1385	Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma. 2012 , 118, 1593-8	14
1384	Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. 2012 , 18, 43-8	16

1383	Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. 2012 , 91, 383-90	29
1382	Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center. 2013 , 35, 165-71	25
1381	Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. 2013 , 31, 22-8	13
1380	Diffuse large B-cell lymphoma of the ocular adnexal region: a nation-based study. 2013 , 91, 163-9	20
1379	Histopathology Reporting. 2013 ,	38
1378	De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression. 2013 , 8, 81	9
1377	High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma. 2013 , 8, 16	7
1376	High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma. 2013 , 34, 1441-50	12
1375	Developments in the immunophenotypic analysis of haematological malignancies. 2013 , 27, 193-207	7
1374	Lymphoma. 2013 ,	1
1373	Cancer Genomics. 2013 ,	4
1372	Nodal Malignant Lymphoma (with Comments on Extranodal Malignant Lymphoma and Metastatic Cancer). 2013 , 377-396	
1371	The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma. 2013 , 8, 243-52	25
1370	Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8). 2013 , 30, 113-29	7
1369	Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures. 2013 , 54, 996-1003	6
1368	Actualit�s th�rapeutiques dans les lymphomes. 2013 ,	
1367	Burkitt's Lymphoma. 2013 ,	1
1366	Nuclear factor-� activation in primary lymphoma of bone. 2013 , 462, 349-54	8

1365	Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. 2013 , 8, 226-35	6
1364	Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL). 2013 , 97, 465-71	11
1363	Large cell lymphoma: correlation of HIV status and prognosis with differentiation profiles assessed by immunophenotyping. 2013 , 19, 695-705	12
1362	Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma. 2013 , 19, 317-22	3
1361	FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. 2013 , 6, 11-18	11
1360	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. 2013 , 62, 1475-84	26
1359	Primary adrenal lymphoma: a systematic review. 2013 , 92, 1583-93	119
1358	Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. 2013 , 92, 1351-8	45
1357	A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components. 2013 , 92, 807-15	12
1356	Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. 2013 , 92, 239-44	21
1355	Relapsed and refractory aggressive NHL: time for a change. 2013 , 49, 72-9	14
1354	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. 2013 , 119, 1195-202	117
1353	Primary cutaneous diffuse large B-cell lymphoma, leg type mimicking cellulitis. 2013 , 31, 104-106	1
1352	Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation. 2013 , 46, 385-7	15
1351	Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. 2013 , 63, 788-801	22
1350	A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. 2013 , 24, 193-201	17
1349	c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma. 2013 , 67, 445-9	1
1348	MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. 2013 , 44, 1375-81	54

1347	Recent advances in de novo CD5+ diffuse large B cell lymphoma. 2013 , 88, 798-802		50
1346	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. 2013 , 163, 611-20		20
1345	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. 2013 , 91 Thesis 5, 1-27		27
1344	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. 2013 , 210, 2273-88		195
1343	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. 2013 , 14, e548-61		17
1342	Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. 2013 , 206, 257-65		18
1341	Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum. 2013 , 54, 967-72		11
1340	Lymphoma. 2013 , 257-278		
1339	Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups. 2013 , 8, 154		1
1338	The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma. 2013 , 2, 27		11
1337	Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. 2013 , 6, 76		13
1336	Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis. 2013 , 2, 19		19
1335	In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. 2013 , 463, 697-711		24
1334	Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. 2013 , 24, 2236-44		65
1333	Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. <i>Blood</i> , 2013 , 122, 1985-6	2.2	45
1332	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013 , 122, 2673-82	2.2	154
1331	Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment. 2013 , 54, 1934-41		12
1330	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). 2013 , 24, 561-76		162

1329	Epstein-Barr virus frequency in primary central nervous system lymphomas in Turkey. 2013 , 121, 232-8		7
1328	Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment. 2013 , 132, 1572-80		37
1327	Diffuse large B-cell lymphoma. 2013 , 87, 146-71		240
1326	Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma. 2013 , 6, 370-81		22
1325	Tissue microarray in a subset of South African patients with DLBCL. 2013 , 49, 120-32		1
1324	Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression. 2013 , 44, 606-11		16
1323	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013 , 121, 4021-31; doi:10.1182/blood-2012-11-4250	2.2	473
1322	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. 2013 , 54, 2606-12		8
1321	Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China. 2013 , 115, 137-43		11
1320	Case report and review of primary bone diffuse large B-cell lymphoma involving the calcaneus. 2013 , 52, 666-72		6
1319	Lymphomas of the Gastrointestinal Tract: An Update. 2013 , 6, 405-24		2
1318	Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma. 2013 , 112, 382-9		12
1317	Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. 2013 , 160, 510-4		12
1316	Clinical applications of BAC array-CGH to the study of diffuse large B-cell lymphomas. 2013 , 973, 121-45		1
1315	MicrRNAs and lymphomagenesis: a functional review. 2013 , 160, 571-81		58
1314	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 121, 3666-74	2.2	100
1313	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013 , 121, 2715-24	2.2	157
1312	Pathology of Non-Hodgkinġ and Hodgkinġ Lymphomas. 2013 , 867-918		

1311	Cytogenetics of Lymphomas. 2013 , 945-984	1
1310	Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. 2013 , 54, 2405-11	34
1309	Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. 2013 , 13, 1305-16	79
1308	Diffuse Large B-Cell Lymphoma. 2013 , 151-173	1
1307	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. 2013 , 381, 1817-26	354
1306	MicroRNAs in hematological malignancies. 2013 , 27, 143-54	45
1305	Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey. 2013 , 209, 471-8	9
1304	Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. 2013 , 37, 386-91	6
1303	MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. 2013 , 97, 223-31	51
1302	EBV primary infection in childhood and its relation to B-cell lymphoma development: a mini-review from a developing region. 2013 , 133, 1286-92	37
1301	Inhibition of miR-21 induces biological and behavioral alterations in diffuse large B-cell lymphoma. 2013 , 130, 87-94	29
1300	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. 2013 , 162, 240-9	8
1299	B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. 2013 , 162, 40-9	64
1298	Molecular pathology of lymphoma. 2013 , 27, 180-9	33
1297	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. 2013 , 54, 2122-30	10
1296	Central nervous system lymphoma in immunocompetent patients: the North Shore-Long Island Jewish Health System experience. 2013 , 20, 75-9	5
1295	DNA repair genes are selectively mutated in diffuse large B cell lymphomas. 2013 , 210, 1729-42	74
1294	Primary testicular lymphoma: experience with 13 cases and literature review. 2013 , 97, 240-5	21

1293	STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma. 2013 , 3, 2173-85	24
1292	Differences in the cytogenetic alteration profiles of diffuse large B-cell lymphoma among Chinese and American patients. 2013 , 206, 183-90	5
1291	Pediatric lymphoma diagnosis: role of FNAC, biopsy, immunohistochemistry and molecular diagnostics. 2013 , 80, 756-63	7
1290	Galectin-3 in pre-B acute lymphoblastic leukemia. 2013 , 27, 2385-8	22
1289	Pathologic diagnosis: molecular genetics. 2013 , 56-81	
1288	Diagnosis and subtyping of de novo and relapsed mediastinal lymphomas by endobronchial ultrasound needle aspiration. 2013 , 188, 1216-23	64
1287	Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. 2013 , 4, 43-57	16
1286	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. 2013 , 24, 1385-92	82
1285	Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. 2013 , 81, 93-4	3
1284	Low incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in Tianjin, northern China. 2013 , 54, 298-303	18
1283	Prognostic significance of hypoxia inducible factor-1 β and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. 2013 , 54, 959-66	8
1282	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. 2013 , 98, 1726-31	94
1281	Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. 2013 , 73, 5029-39	95
1280	Lymphoid proliferations associated with human immunodeficiency virus infection. 2013 , 137, 360-70	37
1279	Pathology of lymphoma in HIV. 2013 , 25, 487-94	40
1278	30 years of lymph node pathology: biomarkers and other advances. 2013 , 21, 103-9	2
1277	Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. 2013 , 21, 116-31	22
1276	The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. 2013 , 25, 470-9	23

1275	Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. 2013 , 31, 58-64	26
1274	Aggressive B-cell lymphomas: how many categories do we need?. 2013 , 26 Suppl 1, S42-56	40
1273	Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. 2013 , 19, 6686-95	91
1272	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. 2013 , 54, 53-7	36
1271	Incidence and clinical significance of aberrant T-cell marker expression on diffuse large B-cell lymphoma cells. 2013 , 130, 230-7	11
1270	MicroRNA profiling in ocular adnexal lymphoma: a role for MYC and NFKB1 mediated dysregulation of microRNA expression in aggressive disease. 2013 , 54, 5169-75	20
1269	Lack of BRAF V600E protein expression in primary central nervous system lymphoma. 2013 , 21, 351-3	7
1268	CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma. 2013 , 162, 87-92	15
1267	The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. 2013 , 162, 657-69	29
1266	Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study. 2013 , 2013, 908191	6
1265	Aberrant expression of CCR4 in diffuse large B-cell lymphoma, not otherwise specified. 2013 , 27, 2382-5	2
1264	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. 2013 , 88, 1062-7	44
1263	Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. 2013 , 88, 774-9	29
1262	Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. 2013 , 98, 615-9	46
1261	Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. 2013 , 288, 35534-47	69
1260	AGENDA AND ABSTRACTS OF SATELLITE SYMPOSIA. 2013 , 31, 279-292	
1259	MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. 2013 , 54, 2149-54	15
1258	CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. 2013 , 88, 273-6	52

1257	Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen. 2013 , 91, 322-31		11
1256	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 121, 2253-63	2.2	393
1255	Flow cytometry is of limited utility in the early identification of "double-hit" B-cell lymphomas. 2013 , 84, 143-8		16
1254	III. Applying molecular phenotyping in practice. 2013 , 31 Suppl 1, 29-32		5
1253	Clinicopathological prognostic indicators in 107 patients with diffuse large B-cell lymphoma transformed from follicular lymphoma. 2013 , 104, 952-7		7
1252	Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. 2013 , 91, 332-8		8
1251	Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy. 2013 , 91, 29-36		2
1250	High prevalence of 1p36 microdeletions in B-cell non-Hodgkin lymphomas (NHL) is associated with PAX7 loss. 2013 , 35, e1-5		
1249	Chromosome abnormalities in diffuse large B-cell lymphomas: analysis of 231 Chinese patients. 2013 , 31, 127-35		5
1248	Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays. 2013 , 7, 802-12		15
1247	High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. 2013 , 3, e139		130
1246	Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. 2013 , 3, e152		42
1245	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. <i>Blood</i> , 2013 , 121, 643-7	2.2	39
1244	Downregulation of FOXP1 is required during germinal center B-cell function. <i>Blood</i> , 2013 , 121, 4311-20	2.2	47
1243	Trimeric G protein-CARMA1 axis links smoothed, the hedgehog receptor transducer, to NF- κ B activation in diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 121, 4718-28	2.2	25
1242	Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. <i>Blood</i> , 2013 , 122, 499-506	2.2	49
1241	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 2233-41	2.2	33
1240	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 1448-54	2.2	18

1239	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. <i>Blood</i> , 2013 , 122, 1256-65	2.2	289
1238	The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. <i>Blood</i> , 2013 , 122, 424-33	2.2	42
1237	Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. 2013 , 37, 323-32		119
1236	Primary testicular diffuse large B-cell lymphoma: A case report focusing on touch imprint cytology and a non-germinal center B-cell-like phenotype. 2013 , 6, 33-36		4
1235	High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma. 2013 , 29, 720-4		16
1234	Primary retroperitoneal diffuse large B-cell lymphoma presenting with numb chin syndrome and painful ophthalmoplegia. 2013 , 52, 1813-9		4
1233	Survival in patients with oral and maxillofacial diffuse large B-cell lymphoma. 2013 , 27, 349-55		5
1232	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. 2013 , 48, 266-73		12
1231	Richter transformation in the brain from chronic lymphocytic leukemia. 2013 , 53, 157-60		5
1230	Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. 2013 , 6, 23-7		
1229	Clinical significance of sIL-2R levels in B-cell lymphomas. 2013 , 8, e78730		33
1228	Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. 2013 , 8, e79863		12
1227	MicroRNA profiling of primary cutaneous large B-cell lymphomas. 2013 , 8, e82471		15
1226	Primary lymphoma of the colon. 2013 , 105, 74-8		14
1225	Primary abdominal muscle lymphoma. 2013 , 2013,		3
1224	Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1. 2014 , 9, e85851		16
1223	Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. 2014 , 9, e93903		23
1222	C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. 2014 , 9, e95020		41

1221	Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. 2014 , 9, e98169	25
1220	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. 2014 , 9, e111840	53
1219	MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. 2014 , 9, e114398	30
1218	Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. 2014 , 49, 162-9	11
1217	Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems. 2014 , 29, 53-60	19
1216	Lymphomatous orbital infiltration and vision loss in diffuse large B-cell lymphoma. 2014 , 2014,	1
1215	Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen. 2014 , 54, 117-27	4
1214	. 2014 ,	1
1213	MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population. 2014 , 31, 306	8
1212	Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study. 2014 , 55, 2721-7	11
1211	A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. 2014 , 53, 669-79	62
1210	Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas. 2014 , 14, 911	19
1209	Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. 2014 , 55, 2071-8	5
1208	Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. 2014 , 55, 2064-70	17
1207	Ocular and Adnexal Lymphoma. 2014 ,	
1206	Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis. 2014 , 16, 728-34	13
1205	Relationship between 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake and clinicopathological factors in patients with diffuse large B-cell lymphoma. 2014 , 55, 520-5	13
1204	Clinical characteristics and treatment outcome in a Taiwanese population of patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. 2014 , 44, 1164-71	13

1203 Molecular Genetics of Diffuse Large B-Cell Lymphoma. **2014**, 1677-1686

1202 Intravascular large B-cell lymphoma diagnosed on prostate biopsy: a case report. **2014**, 31, 403-7

5

1201 One Patient, Two Uncommon B-Cell Neoplasms: Solitary Plasmacytoma following Complete Remission from Intravascular Large B-Cell Lymphoma Involving Central Nervous System. **2014**, 2014, 620423

4

1200 A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome. **2014**, 2014, 120714

5

1199 Implementing a Multi-analyte Immunohistochemistry Panel into a Drug Development Program. **2014**, 345-358

1198 Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. **2014**, 27, 402-11

58

1197 Gene translocations in testicular lymphomas. **2014**, 55, 1410-2

11

1196 IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1). **2014**, 55, 136-42

10

1195 High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. **2014**, 28, 2367-75

239

1194 NFB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. **2014**, 27, 1331-7

26

1193 Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. **2014**, 99, 1817-25

30

1192 Focal adhesion protein expression in human diffuse large B-cell lymphoma. **2014**, 65, 119-31

7

1191 Amplification of 2p as a genomic marker for transformation in lymphoma. **2014**, 53, 750-68

22

1190 p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study. **2014**, 141, 593-604

34

1189 MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. **2014**, 92, 42-8

91

1188 Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. **2014**, 28, 362-72

24

1187 Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. **2014**, 93, 9-18

72

1186 Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. **2014**, 55, 1936-44

49

1185	Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. 2014 , 3, 143-53	24
1184	Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. 2014 , 105, 537-44	45
1183	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. 2014 , 89, 417-22	16
1182	MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. 2014 , 28, 2104-6	44
1181	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. 2014 , 165, 358-63	54
1180	Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. 2014 , 55, 1806-14	17
1179	Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. 2014 , 32, 3996-4003	64
1178	Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas. 2014 , 167, 430-4	
1177	Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. 2014 , 105, 1170-5	52
1176	Adolescents and young adults with non-Hodgkin's lymphoma: slipping between the cracks. 2014 , 132, 279-91	4
1175	High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. 2014 , 38, 1046-57	27
1174	Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. 2014 , 55, 817-23	90
1173	Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis. 2014 , 46, 211-5	14
1172	TNF- β receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. 2014 , 38, 1138-46	6
1171	Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. 2014 , 22, 720-7	19
1170	CNS lymphoma: a practical diagnostic approach. 2014 , 73, 478-94	68
1169	Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. 2014 , 26, 111-7	9
1168	TNF- β expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified. 2014 , 38, 228-34	19

1167	Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. 2014 , 38, 494-501	38
1166	Digital pathology for the validation of tissue microarrays in peripheral T-cell lymphomas. 2014 , 22, 577-84	5
1165	Rare Lymphomas. 2014 ,	
1164	Mature B Cell Neoplasms. 2014 , 108-160	
1163	Cytopathology in Oncology. 2014 ,	3
1162	Lymphomas. 2014 , 251-301	
1161	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. 2014 , 7, 44	59
1160	Genetic and immunohistochemical characterization of Epstein-Barr virus-associated diffuse large B-cell lymphoma. 2014 , 131, 1-10	8
1159	Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. 2014 , 55, 2508-13	19
1158	c-Myc Immunohistochemistry in Diffuse Large B Cell Lymphoma. 2014 , 19, 234-238	1
1157	Genetics of diffuse large B-cell lymphoma: paving a path to personalized medicine. 2014 , 20, 43-7	3
1156	De novo CD5-positive primary cardiac diffuse large B-cell lymphoma diagnosed by pleural fluid cytology. 2014 , 42, 259-67	3
1155	The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. 2014 , 38, 323-8	17
1154	Primary lymphoma of bone: a review. 2014 , 31, 48-52	9
1153	Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas. 2014 , 55, 1158-65	6
1152	Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response. 2014 , 93, 211-9	9
1151	Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. 2014 , 12, 10	32
1150	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). 2014 , 93, 221-231	27

1149	Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. 2014 , 99, 79-86	4
1148	Primary central nervous system Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases. 2014 , 31, 265-73	15
1147	The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. 2014 , 110, 369-74	57
1146	Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. 2014 , 38, 694-8	35
1145	Decision Tools for Radiation Oncology. 2014 ,	2
1144	The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone. 2014 , 464, 229-39	15
1143	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. 2014 , 93, 437-47	15
1142	NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas. <i>Blood</i> , 2014 , 123, 2367-77	2.2 26
1141	Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations. 2014 , 105, 481-9	8
1140	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. 2014 , 25, 2124-2133	110
1139	R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. 2014 , 166, 382-9	24
1138	Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. 2014 , 92, 407-12	51
1137	Expression and significance of leptin receptor, p-STAT3 and p-AKT in diffuse large B-cell lymphoma. 2014 , 116, 126-30	14
1136	Hematopoietic Cell Transplantation in Children with Cancer. 2014 ,	2
1135	Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. 2014 , 20, 1905-11	12
1134	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. 2014 , 42, 927-38	13
1133	LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. 2014 , 165, 640-8	23
1132	Lymphomas and lymphoproliferative diseases of the lung. 2014 , 20, 405-414	5

1131	Prognostic significance of immunophenotypes and a nodular pattern in primary mediastinal large B-cell lymphoma. 2014 , 64, 382-7	1
1130	Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. 2014 , 67, 326-32	21
1129	CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. 2014 , 167, 608-17	62
1128	MicroRNAs: Key Regulators of Oncogenesis. 2014 ,	10
1127	Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. 2014 , 20, 2338-49	96
1126	Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. 2014 , 25, 316-22	35
1125	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. 2014 , 166, 891-901	244
1124	Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression. 2014 , 45, 2043-50	18
1123	Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. 2014 , 14, 460-467.e2	69
1122	De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. 2014 , 32, 282-7	64
1121	Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. 2014 , 4, e220	27
1120	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. 2014 , 15, 1019-26	215
1119	A treatment for activated B-cell-like DLBCL?. 2014 , 15, 916-7	1
1118	Five important advances in hematopathology. 2014 , 138, 410-9	2
1117	Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. 2014 , 20, 5182-93	28
1116	Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. 2014 , 31, 206	2
1115	Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 2014 , 3, 342	2
1114	The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. 2014 , 93, 1755-64	21

1113	Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. 2014 , 465, 351-8	48
1112	Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. 2014 , 93, 617-26	39
1111	Accelerated therapeutic progress in diffuse large B cell lymphoma. 2014 , 93, 541-56	21
1110	Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. 2014 , 93, 1735-43	37
1109	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. 2014 , 93, 1867-77	11
1108	Primary testicular lymphoma. <i>Blood</i> , 2014 , 123, 486-93	2.2 111
1107	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. 2014 , 165, 382-91	126
1106	Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. 2014 , 53, 144-53	60
1105	Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. 2014 , 100, 88-95	15
1104	Switching to BCL-6 Negativity in Relapsed Diffuse Large B Cell Lymphoma Correlated with More Aggressive Disease Course. 2014 , 30, 269-74	1
1103	The diversity of diffuse large B-cell lymphoma in extranodal sites: overview and update. 2014 , 7, 57-70	6
1102	MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. 2014 , 35, 6757-62	16
1101	The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma. 2014 , 93, 500-8	4
1100	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. 2014 , 142, 339-46	26
1099	Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. 2014 , 166, 77-83	35
1098	Large B-cell lymphoma of the base of the tongue and oral cavity: a practical approach to identifying prognostically important subtypes. 2014 , 118, 338-47	13
1097	Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma. 2014 , 105, 437-44	14
1096	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. 2014 , 93, 1263-77	39

1095	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. 2014 , 15, 730-7		135
1094	CD79B and MYD88 mutations in diffuse large B-cell lymphoma. 2014 , 45, 556-64		39
1093	A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. 2014 , 15, e184-93		24
1092	Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. 2014 , 45, 1664-73		42
1091	Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. 2014 , 25, 296-302		25
1090	Primary lymphoma of the central nervous system--a diagnostic challenge. 2014 , 32, 57-67		36
1089	Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?. 2014 , 93, 340-8		23
1088	Epstein-Barr virus-positive diffuse large B-cell lymphoma association is not only restricted to elderly patients. 2014 , 135, 2816-24		40
1087	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014 , 123, 1214-7	2.2	404
1086	Pathology consultation on intermediate-to-large B-cell lymphomas. 2014 , 141, 305-17		6
1085	Rheumatoid arthritis/methotrexate-associated primary cutaneous diffuse large B-cell lymphoma, leg type. 2014 , 53, 1177-81		5
1084	Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. 2014 , 9, e91031		17
1083	Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. 2014 , 12, 797-800		18
1082	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. 2014 , 99, e138-41		2
1081	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. <i>Blood</i> , 2014 , 124, 2544-53	2.2	82
1080	FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF- κ B to promote survival of human B cells. <i>Blood</i> , 2014 , 124, 3431-40	2.2	65
1079	Clinicopathologic Profile and Outcome of Extranodal Diffuse Large B-Cell NHL: Egyptian National Cancer Institute Experience. 2015 , 6, 8-12		1
1078	High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab. 2015 , 102, 662-9		12

1077	Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. 2015 , 106, 1576-81		12
1076	Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. 2015 , 9, 2307-2312		13
1075	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015 , 125, 3118-27	2.2	47
1074	Loss of PRDM11 promotes MYC-driven lymphomagenesis. <i>Blood</i> , 2015 , 125, 1272-81	2.2	14
1073	Ibrutinomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. <i>Blood</i> , 2015 , 125, 236-41	2.2	15
1072	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. <i>Blood</i> , 2015 , 125, 124-32	2.2	59
1071	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. <i>Blood</i> , 2015 , 125, 242-8	2.2	103
1070	The forkhead transcription factor FOXP1 represses human plasma cell differentiation. <i>Blood</i> , 2015 , 126, 2098-109	2.2	36
1069	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2015 , 126, 2193-201	2.2	312
1068	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. <i>Blood</i> , 2015 , 126, 1893-901	2.2	87
1067	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. <i>Blood</i> , 2015 , 126, 2466-74	2.2	159
1066	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , 2015 , 126, 2118-27	2.2	60
1065	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. 2015 , 100, e415-8		3
1064	Interleukin 10 Level in the Cerebrospinal Fluid as a Possible Biomarker for Lymphomatosis Cerebri. 2015 , 54, 1547-52		8
1063	[A Case of Intravascular Lymphoma Mimicking Acute Sinusitis in Which the Outcome was Unfortunate]. 2015 , 118, 770-5		1
1062	Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. 2015 , 5, 12168		65
1061	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. 2015 , 13, 1501-8		26
1060	MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. 2015 , 39, 1250-8		44

1059	Pierwotny chłoniak ośrodkowego układu nerwowego u pacjentów immunokompetentnych. 2015 , 46, 269-279	
1058	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. 2015 , 170, 679-86	18
1057	Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. 2015 , 278, 323-32	26
1056	P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma. 2015 , 15, 722	16
1055	Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. 2015 , 5, 1	4
1054	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. 2015 , 39, 1132-9	53
1053	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. 2015 , 171, 726-35	40
1052	Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features. 2015 , 39, 902-11	12
1051	Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. 2015 , 54, 383-96	31
1050	Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. 2015 , 29, 1943-51	4
1049	Long-term Tumor-free Survival With Untreated Primary Diffuse Large B-cell Lymphoma of the Tonsil: A Report of 9 Cases. 2015 , 39, 1493-501	4
1048	Case Study: Diffuse Large B-Cell Lymphoma Arising in Ovarian Mature Cystic Teratoma. 2015 , 34, 459-64	7
1047	Prognostic value of CD10, BCL-6, MUM-1, and CD138 in diffuse large B-cell lymphoma. 2015 , 35, 95-104	
1046	Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. 2015 , 23, 580-9	8
1045	Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGA7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma. 2015 , 23, 327-33	2
1044	Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. 2015 , 171, 776-83	23
1043	MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. 2015 , 123, 596-603	23
1042	Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis. 2015 , 45, 1147-53	6

1041	High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. 2015 , 65, 528-35	27
1040	Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements. 2015 , 65, 519-27	14
1039	Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. 2015 , 94, e993	40
1038	Aggressive B-cell lymphomas: a review and practical approach for the practicing pathologist. 2015 , 22, 168-80	7
1037	Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes. 2015 , 99, 1036-42	9
1036	Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?. 2015 , e458-66	37
1035	Regulated cell death in diagnostic histopathology. 2015 , 59, 149-58	3
1034	Possible Role of GADD45[Methylation in Diffuse Large B-Cell Lymphoma: Does It Affect the Progression and Tissue Involvement?. 2015 , 32, 295-303	1
1033	MicroRNA 21 Expression Levels in HIV Negative and HIV Positive Diffuse Large B Cell Lymphoma. 2015 , 04,	1
1032	MicroRNAs as B-cell lymphoma biomarkers. 2015 , 25	1
1031	Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults. 2015 , 115	
1030	The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. 2015 , 11, 708-14	13
1029	Immunohistochemical subtypes of diffuse large B-cell lymphoma in the head and neck region. 2015 , 14, 3889-96	4
1028	miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. 2015 , 16, 18077-95	46
1027	Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. 2015 , 7, 6067	23
1026	The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. 2015 , 10, e0126615	16
1025	Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission. 2015 , 10, e0133469	6
1024	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. 2015 , 10, e0136476	43

1023	A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. 2015 , 10, e0145037	2
1022	SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. 2015 , 2015, 841769	12
1021	MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. 2015 , 16, 349-58	18
1020	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. 2015 , 17, 1016-21	36
1019	Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. 2015 , 39, 61-6	29
1018	Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study. 2015 , 133, 165-73	41
1017	Case records of the Massachusetts General Hospital. Case 18-2015. A 41-year-old woman with decreased vision in the left eye and diplopia. 2015 , 372, 2337-45	2
1016	QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma. 2015 , 17, 402-11	9
1015	Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis. 2015 , 36, 7269-75	19
1014	Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly. 2015 , 46, 716-24	36
1013	Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP. 2015 , 68, 733-8	12
1012	Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2015 , 125, 2579-81	2.2 81
1011	Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation. 2015 , 123, 413-20	15
1010	FilGAP, a Rac-specific Rho GTPase-activating protein, is a novel prognostic factor for follicular lymphoma. 2015 , 4, 808-18	16
1009	Diffuse large B cell lymphoma of the cranial vault: two case reports. 2015 , 32, 275-80	10
1008	Update in large cell lymphoma: understanding the pathology report. 2015 , 2015, 605-17	3
1007	Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach. 2015 , 2015, 618-24	8
1006	miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. 2015 , 14, 185	32

1005	The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. 2015 , 56, 676-81	5
1004	Oncogenic MYD88 mutations are rare events in double-hit B-cell lymphomas. 2015 , 133, 113-5	2
1003	Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. 2015 , 6, 141-52	47
1002	Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. 2015 , 121, 1032-9	27
1001	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. 2015 , 56, 2032-8	33
1000	Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. 2015 , 56, 2039-46	9
999	Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era. 2015 , 39, 211-5	6
998	Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era. 2015 , 46, 49-55	
997	The genetic landscape of diffuse large B-cell lymphoma. 2015 , 52, 67-76	125
996	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. 2015 , 56, 2895-901	23
995	Genetic lesions in diffuse large B-cell lymphomas. 2015 , 26, 1069-1080	52
994	The histological classification of diffuse large B-cell lymphomas. 2015 , 52, 57-66	48
993	Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. 2015 , 56, 2563-8	27
992	Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases. 2015 , 100, 754-62	7
991	Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. 2015 , 29, 1564-70	41
990	Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. 2015 , 168, 663-70	25
989	Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. 2015 , 94, 609-16	7
988	EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?. 2015 , 26, 548-55	48

987	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. 2015 , 28, 208-17		60
986	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015 , 125, 22-32	2.2	34 ⁰
985	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly. 2015 , 56, 1100-6		32
984	When and how to test for C-MYC in aggressive B cell lymphomas. 2015 , 8, 13-20		2
983	High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. 2015 , 101, 140-7		10
982	Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?. 2015 , 8, 48-51		0
981	Generalized Alternating Direction Method of Multipliers: New Theoretical Insights and Applications. 2015 , 7, 149-187		41
980	miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma. 2015 , 36, 5377-88		12
979	Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus. 2015 , 466, 85-92		7
978	The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. 2015 , 94, 57-63		24
977	Plasmablastic lymphoma versus diffuse large B cell lymphoma with plasmablastic differentiation: proposal for a novel diagnostic scoring system. 2015 , 8, 3-11		7
976	MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. 2015 , 19, 372-8		7
975	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. 2015 , 33, 2848-56		236
974	Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas. 2015 , 139, 1094-107		26
973	Surgical Pathology of Liver Tumors. 2015 ,		4
972	Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study. 2015 , 15, 398-403		6
971	Tropical Hemato-Oncology. 2015 ,		2
970	Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified. 2015 , 94, 1655-65		17

969	Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. 2015 , 467, 345-55		12
968	Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. 2015 , 29, 1857-67		19
967	Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. 2015 , 102, 188-94		20
966	Primary Bone Lymphoma: A Clinical Analysis of 17 Patients in a Single Institution. 2015 , 134, 80-5		16
965	Gene expression profiling in non-Hodgkin lymphomas. 2015 , 165, 97-123		2
964	Atlas of Cutaneous Lymphomas. 2015 ,		0
963	Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association. 2015 , 6, 8-14		14
962	Pediatric non-Hodgkin lymphomas: first report from Central Africa. 2015 , 32, 239-49		7
961	Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development. 2015 ,		
960	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. 2015 , 26, 1058-1068		52
959	Clinicopathological correlates of primary central nervous system lymphoma: experience from a tertiary care center in South India. 2015 , 63, 77-82		9
958	A 58-year-old lady with progressive neurological syndrome: Presence of an intravascular lymphoma. 2015 , 63, 225-9		2
957	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015 , 125, 3679-87	2.2	190
956	Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study. 2015 , 15, 159-63		2
955	Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. 2015 ,		40
954	Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. 2015 , 15, 208-13		27
953	Immunohistochemical prognostication in diffuse large B-cell lymphoma: a single center 6-year retrospective analysis. 2015 , 56, 2975-7		1
952	Recent advances in intestinal lymphomas. 2015 , 66, 112-36		43

951	CK2 β phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients. 2015 , 136, 797-809	37
950	Primary diffuse large B-cell lymphoma of the ovary is of a germinal centre B-cell-like phenotype. 2015 , 466, 93-100	10
949	Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. 2015 , 39, 382-7	5
948	Pathology of B-cell lymphomas: diagnosis and biomarker discovery. 2015 , 165, 27-50	8
947	Molecular Pathogenesis of B Cell Lymphomas. 2015 , 399-416	
946	Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. 2015 , 33, 1379-88	73
945	Treatment approach to newly diagnosed diffuse large B-cell lymphoma. 2015 , 52, 107-18	14
944	A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection. 2015 , 21, 1429-37	16
943	An oncogenic role for alternative NF- κ B signaling in DLBCL revealed upon deregulated BCL6 expression. 2015 , 11, 715-26	57
942	Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System. 2015 , 21, 2367-78	55
941	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. 2015 , 56, 2630-6	11
940	Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma. 2015 , 23, 188-95	8
939	Epstein-Barr virus (EBV)-positive sporadic burkitt lymphoma: an age-related lymphoproliferative disorder?. 2015 , 39, 227-35	23
938	Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String". 2015 , 21, 2204-6	1
937	Diffuse large B-cell lymphoma of germinal center and nongerminal center phenotypes presenting concurrently at the same anatomic site: intratumoral heterogeneity or composite lymphoma?. 2015 , 23, 78-80	
936	Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. 2015 , 67, 625-35	18
935	The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma. 2015 , 56, 2945-52	10
934	Diffuse Large B-Cell Lymphoma of the Frontal Sinus Presenting as a Pott Puffy Tumor: Case Report. 2015 , 76, e23-7	3

933	Machine Learning-based Classification of Diffuse Large B-cell Lymphoma Patients by Their Protein Expression Profiles. 2015 , 14, 2947-60	58
932	Several immune escape patterns in non-Hodgkin's lymphomas. 2015 , 4, e1026530	62
931	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. 2015 , 5, 1058-71	78
930	Expression and pro-survival function of phospholipase C α in diffuse large B-cell lymphoma. 2015 , 56, 1088-95	3
929	The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review. 2015 , 34, 511-25	1
928	Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. 2015 , 56, 1677-85	26
927	Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. 2015 , 171, 145-8	12
926	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. 2015 , 90, 1041-6	50
925	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. 2015 , 4, e1026503	25
924	The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. 2015 , 390, 315-37	15
923	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2015 , 26 Suppl 5, v116-25	397
922	Diffuse large B-cell lymphoma and Burkitt lymphoma. 2015 , 21, 391-399	
921	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. 2015 , 33, 3930-7	19
920	A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve. 2015 , 15, e117-20	8
919	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. 2015 , 28, 1202-13	15
918	Next-generation prognostic assessment for diffuse large B-cell lymphoma. 2015 , 11, 2443-57	7
917	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. 2015 , 99, 537-45	12
916	Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. 2015 , 33, 3215-6	5

915	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees. 2015 , 33, 2835-6	15
914	Non-Hodgkin Lymphoma: Diagnosis and Treatment. 2015 , 90, 1152-63	68
913	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. 2015 , 21, 1199-208	247
912	STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma. 2015 , 124, 165-74	11
911	Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas. 2015 , 113, 934-44	20
910	Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. 2015 , 94, 1865-73	12
909	Lymphoma and Lymphoproliferative Disorders. 2015 , 619-644	
908	Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. 2015 , 5, e346	48
907	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. 2015 , 56, 2613-8	7
906	CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. 2015 , 467, 571-82	22
905	Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. 2015 , 102, 678-88	5
904	Speaker Presentations. 2015 , 39, S1-S18	1
903	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. 2015 , 100, 238-45	62
902	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. 2015 , 169, 188-98	42
901	Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. 2015 , 17, 19-30	19
900	Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?. 2015 , 263, 173-91	51
899	HHV8-negative effusion based lymphoma: a series of 17 cases at a single institution. 2015 , 4, 37-43	8
898	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. 2015 , 56, 1020-6	23

- 897 Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR. **2015**, 95, 113-20 12
- 896 Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma. **2015**, 139, 602-7 11
- 895 Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. **2015**, 168, 654-62 64
- 894 Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. **2015**, 56, 2141-5 62
- 893 Tumors of Lymphoid and Hematopoietic Tissues. **2015**, 103-149
- 892 Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma. **2015**, 56, 1930-7 4
- 891 Linfoma B difuso de células grandes primario testicular. Presentación de 3 casos y revisión de la literatura. **2015**, 48, 97-102
- 890 Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. **2015**, 56, 1742-9 9
- 889 Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. **2015**, 94, 219-26 10
- 888 Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. **2015**, 33, 251-7 268
- 887 Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus. **2015**, 32, 229-38 5
- 886 Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics. **2016**, 1015-1035
- 885 Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. **2016**, 1, 84-92 6
- 884 Genetic analysis of B-cell lymphomas associated with hemophagocytic lymphohistiocytosis. **2016**, 1, 205-207 3
- 883 [Recent advances in the understanding and treatment of diffuse large B-cell lymphoma]. **2016**, 157, 1232-41
- 882 Twenty Years of Autologous Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma: A Single Portuguese Center Experience. **2016**, 29, 205-9 1
- 881 Ocular Adnexal Lymphoma: Clinical Presentation, Diagnosis, Treatment and Prognosis. **2016**, 07, 1
- 880 Oct2, BCL6, IRF8, OCAB and PU.1 in the Assessment of Prognosis in Diffuse Large B cell Lymphoma Patients. **2016**, 07, 1

879	Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes. 2016 , 9, 2069-80	10
878	Risk factors and patterns of lymph node involvement in primary gastric large B-cell lymphoma: implications for target definition. 2016 , 9, 4757-62	2
877	A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. 2016 , 7, 72197-72210	6
876	Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytogh̃tique h̃matologique (GFCH). 2016 , 74, 568-587	2
875	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. 2016 , 7, 76934-76943	22
874	Diffuse large B-cell lymphoma. 2016 , 22, 159-166	1
873	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. 2016 , 5,	7
872	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. 2016 , 7, 18036-49	19
871	An Unusual Case of Extranodal Diffuse Large B-Cell Lymphoma Infiltrating Skeletal Muscle: A Case Report and Review of the Literature. 2016 , 2016, 9104839	7
870	Primary Diffuse Large B-Cell Lymphoma of the Liver in a Patient with Sjogren Syndrome. 2016 , 2016, 2053257	4
869	miR-155 as a Biomarker in B-Cell Malignancies. 2016 , 2016, 9513037	38
868	The Comparative Diagnostic Features of Canine and Human Lymphoma. 2016 , 3,	36
867	Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. 2016 , 56, 89-99	26
866	Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma. 2016 , 7,	14
865	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. 2016 , 16, 363	32
864	Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. 2016 , 56, 100-108	10
863	WNT2 Promotes Cervical Carcinoma Metastasis and Induction of Epithelial-Mesenchymal Transition. 2016 , 11, e0160414	24
862	hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. 2016 , 11, e0163711	7

861	Primary Non-Hodgkin's Lymphoma of the Vulva: A Case Report and Literature Review. 2016 , 95, e3041	17
860	Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. 2016 , 37, 689-98	9
859	Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma. 2016 , 174, 264-74	10
858	MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. 2016 , 68, 1090-8	56
857	Primary Intestinal Diffuse Large B-cell Lymphoma in Taiwan Showed a Relative Higher Rate of Perforation and EBV Association. 2016 , 24, 541-9	4
856	Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. 2016 , 104, 485-90	22
855	Clinical approach to diffuse large B cell lymphoma. 2016 , 30, 477-491	19
854	Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. 2016 , 174, 686-91	26
853	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. 2016 , 140, 1225-1227	3
852	CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. 2016 , 97, 39-47	14
851	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. 2016 , 122, 559-64	49
850	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. 2016 , 124, 135-43	23
849	Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma. 2016 , 173, 582-96	10
848	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. 2016 , 12, 1553-63	66
847	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. 2016 , 91, 179-84	30
846	Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. 2016 , 29, 1118-42	18
845	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. 2016 , 122, 2680-8	31
844	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features. 2016 , 16, 414-25	51

843	Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. 2016 , 96, 492-501		11
842	Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry. 2016 , 60, 372-384		18
841	Lymph Node Fine-Needle Cytology of Non-Hodgkin Lymphoma: Diagnosis and Classification by Flow Cytometry. 2016 , 60, 302-314		32
840	A Basic Approach to Lymph Node and Flow Cytometry Fine-Needle Cytology. 2016 , 60, 284-301		13
839	The distinct clinical features and prognosis of the CD10+MUM1+ and CD10?Bcl6?MUM1? diffuse large B-cell lymphoma. 2016 , 6, 20465		16
838	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. 2015 , 5, 17868		11
837	B-Zell-Lymphome der Haut - Pathogenese, Diagnostik und Therapie. 2016 , 14, 1207-1225		0
836	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. <i>Blood</i> , 2016 , 127, 2732-41	2.2	78
835	Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. 2016 , 107, 1572-1580		5
834	Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy. 2016 , 14, 1207-1224		13
833	DA-EPOCH-R: An alternative treatment for high-risk diffuse large B cell lymphoma?. 2016 , 9, 178-182		
832	Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. 2016 , 2016, 589-597		31
831	Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. 2016 , 37, 1095-101		11
830	[Hodgkin and non-Hodgkin lymphoma of adolescents and young adults]. 2016 , 103, 1035-1049		2
829	Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. 2016 , 30, 1568-79		16
828	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. 2016 , 34, 2484-92		81
827	Helicobacter pylori Infection and MALT Lymphoma. 2016 , 423-441		1
826	Evaluation of CD25-positive cells in relation to the subtypes and prognoses in various lymphoid tumours in dogs. 2016 , 173, 39-43		8

825	MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. 2016 , 136, 1741-1744		33
824	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. 2016 , 9, 41-54		4
823	FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. 2016 , 30, 605-16		44
822	Oncogenic CARMA1 couples NF- κ B and β -catenin signaling in diffuse large B-cell lymphomas. 2016 , 35, 4269-81		31
821	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. 2016 , 64, 225-40		9
820	A unique subtype of diffuse large B-cell lymphoma primarily involving the bone marrow, spleen, and liver, defined by fluorodeoxyglucose-positron emission tomography combined with computed tomography. 2016 , 57, 2593-602		9
819	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. 2016 , 57, 2784-2790		13
818	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. 2016 , 29, 685-97		43
817	Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center. 2016 , 57, 2791-2803		1
816	Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression. 2016 , 29, 844-53		4
815	Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy. 2016 , 145, 514-23		27
814	Primitive "Spindle Cell Variant" (Sarcomatoid Variant) Diffuse Large B-Cell Lymphoma of the Uterine Cervix: Description and Outcome of a Rare Case. 2016 , 35, 593-597		7
813	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. 2016 , 22, 1543-1551		34
812	Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. 2016 , 57, 2820-2826		11
811	Helicobacter pylori Research. 2016 ,		3
810	CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. <i>Blood</i> , 2016 , 127, 1780-9	2.2	27
809	Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. <i>Blood</i> , 2016 , 127, 181-6	2.2	19
808	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016 , 127, 411-9	2.2	195

807	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016 , 127, 2182-8	2.2	105
806	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. <i>Blood</i> , 2016 , 127, 3026-34	2.2	126
805	Korean Red Ginseng water extract arrests growth of xenografted lymphoma cells. 2016 , 40, 431-436		22
804	Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era. 2016 , 6, e477		4
803	Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. 2016 , 5, 2740-2755		28
802	Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?. 2016 , 16, 655-661		3
801	ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. 2016 , 27, 2149-2160		13
800	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. 2021 , 104, 106552		1
799	Revisiting the Full Spectrum of Helicobacter pylori-Related Gastric Lymphoma.		
798	Outcome of Diffuse Large B-Cell Lymphoma with First-line Chemotherapy. 2021 , 5, 03-09		
797	Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein-Barr virus infection in Nigeria population. 2021 , 16, 36		0
796	Polymyalgia rheumatica-like presentation in a case of diffuse large B-cell lymphoma: a diagnostic pitfall. 2021 , 49, 3000605211018595		
795	Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma. 2021 , 13,		8
794	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. 2021 , 106, 2682-2693		12
793	Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach.. 2022 , 38, 223-234		
792	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. 2021 , 27, 404.e1-404.e5		1
791	A Prognostic Model of Gastrointestinal Diffuse Large B Cell Lymphoma. 2021 , 27, e929898		0
790	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP + ibrutinib. 2021 , 194, 83-91		2

789	A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. 2021 , 125, 402-412		3
788	An approach to small lymph node biopsies: pearls and pitfalls of reporting in the real world. 2021 , 10, 328-337		0
787	Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with and / rearrangements, especially in germinal center cell-type tumors. 2021 , 62, 2547-2550		
786	Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration. 2021 , 2021, 9995869		1
785	Primary breast lymphoma initially diagnosed as invasive ductal carcinoma: A case report. 2021 , 9, e04189		2
784	Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. 2021 , 11, 95		0
783	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. 2021 , 10, 5101-5109		1
782	Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients. 2021 , 62, 2360-2373		
781	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. <i>Blood</i> , 2021 , 138, 1194-1197	2.2	1
780	Molecular classification of aggressive lymphomas-past, present, future. 2021 , 39 Suppl 1, 24-30		0
779	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing. 2021 , 13,		1
778	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma. 2021 , 71, 594-603		
777	Application of mid-infrared microscopic imaging for the diagnosis and classification of human lymphomas. 2021 , 14, e202100079		0
776	Primary non-Hodgkin diffuse large B-cell lymphoma of the lacrimal sac: a rare case of aggressive tumor and literature review. 2021 , 94, 377-381		
775	Mediastinal Lymphoproliferative Disorders. 2021 , 28, 307-334		0
774	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. 2021 , 11, 113		6
773	Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients. 2021 , 41,		
772	Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients. 2021 , 11, 2509-2520		2

771	Intravascular lymphoma presenting with hypoxaemia, platypnoea and lactic acidosis. 2021 , 14,	1
770	Outcomes of diffuse large B-cell lymphoma in elderly patients-real-world experience from a middle-income country setting. 2021 , 15, 1242	
769	Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis. 2021 , 50, 587-593	2
768	CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS. 2021 , 41, 2596-2604	1
767	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. 2021 , 11, 638154	1
766	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.. 2021 , 10, 2632-2642	
765	CD5+ diffuse large B-cell lymphoma: a narrative review. 2021 , 62, 3078-3086	3
764	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. 2021 , 194, 870-878	3
763	CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma. 2021 , 39, 483-489	2
762	Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. 2021 , 106, 2774-2778	3
761	Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial. 2021 , 9, e1008-e1016	5
760	Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma. 2021 , 127, 3991-3997	1
759	A case of diagnosis of diffuse large b-cell lymphoma with extranodular cervical disease. 2021 , 84-90	
758	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. 2021 , 113, 9-19	0
757	MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience. 2021 , 3, vdab090	1
756	Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development. 2021 , 38, 173-182	2
755	Molecular Update and Evolving Classification of Large B-Cell Lymphoma. 2021 , 13,	4
754	The miRNA content of circulating exosomes in DLBCL patients and in vitro influence of DLBCL-derived exosomes on miRNA expression of healthy B cells from peripheral blood. 2021 ,	1

753	Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study. 2021 , 1	0
752	A case report of secondary neurolymphomatosis showing selective nerve infiltration and massive lumbar plexus enlargement. 2021 , 21, 296	
751	Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. 2021 ,	1
750	Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases. 2021 , 41, 335-348	0
749	Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing. 2021 , 17, 4171-4183	2
748	Pediatric hematolymphoid pathology in the gastrointestinal tract. 2021 , 38, 31-37	
747	In situ transcriptional profile of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched Diffuse Large B-cell Lymphomas.	1
746	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients. 2021 , 195, 399-404	0
745	Update on B-cell lymphoproliferative disorders of the gastrointestinal tract. 2021 , 38, 14-20	0
744	Sinonasal Lymphoma: Extranodal Natural Killer/T-Cell Lymphoma and Its Differential Diagnosis. 2021 , 26, 226-239	
743	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. 2021 ,	2
742	The Prognostic Significance of the BIN1 and CCND2 Gene in Adult Patients with Acute Myeloid Leukemia. 1	
741	Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art. 2021 , 17, 1459-1485	1
740	Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunoglobulin heavy chain rearrangement. 2021 , 9, e04657	0
739	Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features. 2021 , 13,	3
738	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. 2021 , 21, 972	0
737	Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial. 2021 ,	0
736	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. 2021 ,	

735	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. 2021 , 39, 473-482	1
734	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. 2022 , 30, 49-55	
733	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort. 2021 , 195, 731-742	3
732	Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. 2021 , 100, 2969-2978	1
731	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma. 2021 , 7, 604-615	0
730	Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features. 2021 , 53, 595-601	1
729	A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. 2021 , 1-10	3
728	The genomic and transcriptional landscape of primary central nervous system lymphoma.	0
727	Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. 2021 , 5, 3227-3239	3
726	Prognostication of Primary Tumor Location in Early-Stage Nodal Diffuse Large B-Cell Lymphoma: An Analysis of the SEER Database. 2021 , 13,	0
725	A dome-shaped nodule on unattached alveolar mucosa. 2021 ,	
724	Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma. 2021 , 1	
723	Current progress and future perspectives of research on intravascular large B-cell lymphoma. 2021 , 112, 3953-3961	3
722	Screening and identification of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarray. 2021 , 22, 753	2
721	Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. 2021 , 195, 201-209	5
720	Bone Marrow and Peripheral Blood Evaluation in Non-Hodgkin Lymphoma [A Cross Sectional Study of 78 Cases in a Tertiary Care Centre in Kerala. 2021 , 8, 2943-2949	
719	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. 2021 , 5, 3760-3775	3
718	translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival. 2021 , 1-8	1

7 ¹⁷	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2021 ,	2.2	6
7 ¹⁶	Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells. 2021 , 45, 1606-1615		2
7 ¹⁵	Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience. 2021 , 21, 498		1
7 ¹⁴	Cutaneous involvement in diffuse large B cell lymphoma at presentation: report of two rare cases and literature review. 2021 , 33, 25		0
7 ¹³	Molecular Pathology of Mature Lymphoid Malignancies. 2021 , 14, 529-547		
7 ¹²	Prognostic significance of immunohistochemical markers in Primary CNS lymphomas. 2021 , 6, 160-165		
7 ¹¹	Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease pathogenesis and treatment. 2021 , 27, 5932-5945		2
7 ¹⁰	HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma. 2021 ,		1
7 ⁰⁹	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. 2021 , 39, 1422-1437.e10		15
7 ⁰⁸	Viability of diffuse large B-cell lymphoma cells is regulated by kynurenine 3-monooxygenase activity. 2021 , 22, 790		1
7 ⁰⁷	Update on Pediatric and Young Adult Mature Lymphomas. 2021 , 41, 359-387		0
7 ⁰⁶	MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis. 2021 , 208, 106838		1
7 ⁰⁵	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. 2021 , 55, 330-337		1
7 ⁰⁴	Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study. 2021 ,		0
7 ⁰³	Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience.		
7 ⁰²	Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance. 2021 ,		1
7 ⁰¹	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2021 ,	2.2	10
7 ⁰⁰	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. 2021 , 11, 638757		2

699	Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases. 2021 , 195, 585-594	0
698	GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/ β -catenin signaling pathway. 2021 , 710, 108998	2
697	Primary diffuse large B-cell lymphoma of the sigmoid colon. 2021 , 87, 106454	0
696	Resistant rhinosinusitis?. 2021 , 138, 407-408	
695	Une rhinosinusite r�sistante?. 2021 , 138, 409-410	
694	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. 2021 , 110, 106715	1
693	Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma. 2021 , 110, 106700	
692	Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis. 2021 , 111, 106693	1
691	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. 2021 , 11, 1886	6
690	Intravascular large B-cell lymphoma with diffuse ground glass lesion on chest computed tomography diagnosed using transbronchial lung cryobiopsy: a case report.. 2021 , 10, 4571-4576	2
689	Biomarker barcodes: multiplexed microfluidic immunohistochemistry enables high-throughput analysis of tissue microarray. 2021 , 21, 3471-3482	3
688	Oncological Mimics in Inflammatory CNS Disease. 2021 , 417-430	0
687	The impact of cell-of-origin, MYC/Bcl-2 dual expression and rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. 2021 , 62, 1361-1369	0
686	Clinical characteristics and treatment outcomes of diffuse large B-cell lymphoma involving the eye and ocular adnexa in East Asia. 2021 , 99, 773-782	1
685	Germinal Center Cells Turning to the Dark Side: Neoplasms of B Cells, Follicular Helper T Cells, and Follicular Dendritic Cells. 2020 , 10, 587809	3
684	Linfoma primario de p�ncreas como simulador cl�nico de carcinoma pancre�tico: un problema de diagn�stico diferencial con manejo terap�utico dispar. 2021 ,	0
683	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. 2021 , 16, e0237554	7
682	B Cell Expansion and Neoplasia in Sj�gren� Syndrome. 2021 , 117-136	

681	Polyomavirus SV40 and AIDS-related systemic non-Hodgkin's lymphoma. 2007 , 133, 215-40	2
680	Pathology of Primary Central Nervous System Lymphoma and Related Conditions. 2012 , 61-86	3
679	The Non-Hodgkin's Lymphomas. 2007 , 237-270	3
678	Integrative oncogenomic analysis of microarray data in hematologic malignancies. 2010 , 576, 231-77	5
677	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. 2019 , 41-73	1
676	Soft Tissue and Lymph Nodes of the Head and Neck. 2019 , 277-329	1
675	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. 2020 , 215, 213-230	7
674	Lymphoma. 2020 , 327-340	1
673	Introduction to the B-Cell Lymphomas. 2015 , 139-151	1
672	Diffuse Large B-Cell Lymphomas in Older Adults. 2020 , 583-612	1
671	Ocular and Adnexal Lymphoma: Molecular Pathology. 2014 , 25-46	2
670	Cytopathology in the diagnosis of lymphoma. 2014 , 160, 211-40	5
669	EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly. 2012 , 83-98	1
668	Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCN-PI subgroup by MTV in DLBCL. 2021 , 35, 24-30	7
667	DNA Microarrays in Biological Discovery and Patient Care. 2009 , 157-172	2
666	Non-Hodgkin's Lymphoma. 2008 , 2371-2404	3
665	Lymphomas and Histiocytic Tumors. 2010 , 315-332	2
664	Molecular Diagnosis in Hematopathology. 2011 , 56-80	2

663	Diffuse Large B-Cell Lymphoma. 2011 , 349-381	4
662	Molecular Diagnosis of the Lymphomas by Gene Expression Profiling. 2006 , 110-126	1
661	Malignant Lymphomas and Lymphadenopathies. 2009 , 417-505	4
660	Diffuse Aggressive B-Cell Lymphomas. 2012 , 261-292	1
659	Non-Hodgkin Lymphoma. 2014 , 2033-2059.e8	1
658	Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. 2018 , 59, 1260-1263	10
657	Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas. 2021 , 218,	6
656	Diffuse Large B-Cell Lymphoma With Extra Bcl-2 Gene Signals Detected by FISH Analysis Is Associated With a Non-Germinal Center Phenotype□ 2005 , 29, 1067-1073	23
655	Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma. 2005 , 29, 1086-1094	114
654	Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography. 2020 , 99, e20140	2
653	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. 2020 , 28, 731-740	4
652	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China. 2020 , 44, 1602-1611	3
651	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. 2020 , 10,	1
650	Gene expression profiling of primary vitreoretinal lymphoma. 2020 , 111, 1417-1421	11
649	Combination of CD47 and signal-regulatory protein-β constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma. 2020 , 111, 2608-2619	9
648	Recent advances upper gastrointestinal lymphomas: molecular updates and diagnostic implications. 2021 , 78, 187-214	4
647	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. 2021 , 2, 70-91	7
646	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. 2015 , 125, 4559-71	34

645	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. 2016 , 126, 3351-62	92
644	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. 2012 , 2012, 402-409	46
643	Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cell Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow.. <i>Blood</i> , 2006 , 108, 2042-2042 ²⁻²	1
642	High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study. 2016 , 22, 1792-800	1
641	Long Non-Coding RNA Paternally Expressed Imprinted Gene 10 (PEG10) Elevates Diffuse Large B-Cell Lymphoma Progression by Regulating Kinesin Family Member 2A (KIF2A) via Targeting MiR-101-3p. 2020 , 26, e922810	5
640	Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. 2018 , 7,	2
639	EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. 2011 , 6, e28585	98
638	SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. 2012 , 7, e45119	87
637	Expression of BAFF and BAFF-R in follicular lymphoma: correlation with clinicopathologic characteristics and survival outcomes. 2012 , 7, e50936	20
636	A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma. 2013 , 8, e55895	46
635	Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma. 2013 , 8, e57677	8
634	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. 2014 , 9, e104068	31
633	Control of asymmetric Hopfield networks and application to cancer attractors. 2014 , 9, e105842	11
632	The truncate mutation of Notch2 enhances cell proliferation through activating the NF- κ B signal pathway in the diffuse large B-cell lymphomas. 2014 , 9, e108747	22
631	Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade. 2014 , 9, e108861	29
630	Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. 2015 , 10, e0133973	16
629	Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. 2016 , 11, e0146624	5
628	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. 2016 , 11, e0156384	16

627	Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing. 2016 , 11, e0167599	8
626	mTOR activity in AIDS-related diffuse large B-cell lymphoma. 2017 , 12, e0170771	1
625	Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer. 2020 , 35, 721-728	3
624	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. 2017 , 37, 535-546	16
623	Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case. 2020 , 15, 119-125	17
622	Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. 2010 , 128, 14-7	5
621	[Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors]. 2019 , 81, 59-65	21
620	[Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma]. 2015 , 87, 77-85	1
619	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. 2016 , 7, 59976-59986	45
618	GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. 2016 , 7, 65284-65294	21
617	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. 2016 , 7, 86433-86445	51
616	Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients. 2017 , 8, 9708-9716	7
615	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). 2017 , 8, 13367-13374	6
614	Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 2017 , 8, 13782-13791	16
613	Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma. 2017 , 8, 19556-19565	8
612	The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma. 2017 , 8, 34374-34386	14
611	Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. 2017 , 8, 33487-33500	15
610	and polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. 2017 , 8, 58292-58303	5

609	Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients. 2017 , 8, 73168-73176	7
608	Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?. 2014 , 5, 1912-25	19
607	Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor and. 2017 , 8, 78480-78495	3
606	The prognostic significance of CD11bCX3CR1 monocytes in patients with newly diagnosed diffuse large B-cell lymphoma. 2017 , 8, 92289-92299	4
605	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. 2018 , 9, 11441-11450	14
604	Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to diffuse large B-cell lymphoma. 2018 , 9, 19613-19622	6
603	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. 2018 , 9, 29753-29771	9
602	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. 2015 , 6, 6553-69	47
601	Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. 2020 , 11, 4045-4073	4
600	A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. 2014 , 5, 11813-26	28
599	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. 2015 , 6, 9488-501	24
598	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. 2015 , 6, 6544-52	27
597	MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. 2015 , 6, 18374-88	42
596	Neutrophils trigger a NF- κ B dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. 2015 , 6, 16471-87	45
595	Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. 2015 , 6, 25061-73	38
594	Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. 2016 , 7, 2391-400	34
593	Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. 2015 , 6, 43881-96	36
592	Angiomirs expression profiling in diffuse large B-Cell lymphoma. 2016 , 7, 4806-16	20

591	SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients. 2013 , 4, 35-47	39
590	Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. 2016 , 7, 38122-38132	20
589	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. 2016 , 7, 51494-51502	27
588	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. 2019 , 31, 152-161	31
587	Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. 2019 , 19, 1325-1339	1
586	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. 2018 , 19, 1229-1236	6
585	Tissue microarray: A valuable method in diagnosis and prognosis of hematological malignances. 2005 , 13, 131-135	1
584	Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells. 2009 , 66, 738-43	12
583	Primary cutaneous B-cell lymphoma: narrative review of the literature. 2019 , 154, 466-479	3
582	A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes. 2019 , 53, 473-479	2
581	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India. 2020 , 11, 424	2
580	Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach. 2020 , 112, 227-247	4
579	Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. 2020 , Online ahead of print,	5
578	Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience. 2008 , 49, 618-24	4
577	CHEMOTHERAPY ACCORDING TO THE R-mNHL-BFM-90 PROTOCOL IN COMBINATION WITH LENALIDOMIDE AS THE FIRST LINE THERAPY IN PATIENTS WITH MUM1-POSITIVE DIFFUSIVE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA GRADE 3B. 2019 , 64, 150-164	1
576	Construction and analysis of tree models for chromosomal classification of diffuse large B-cell lymphomas. 2007 , 13, 1737-42	5
575	Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR. 2020 , 22, 1243-1256	5
574	Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. 2014 , 29, 352-60	21

573	Clinical significance of nuclear factor B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. 2014 , 29, 785-92	14
572	Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party. 2016 , 31, 1030-1041	12
571	Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. 2017 , 32, 335-344	4
570	A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus. 2016 , 143, 605-15	12
569	Primary central nervous system lymphoma in immunocompetent patients: A regional cancer center experience. 2017 , 6, 165-168	4
568	High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma. 2020 , 10, 241-248	2
567	Diffused mixed B-cell non-Hodgkin lymphoma of mandible. 2020 , 24, S77-S81	1
566	Machine Learning Provides an Accurate Classification of Diffuse Large B-Cell Lymphoma from Immunohistochemical Data. 2018 , 9, 21	4
565	The expression level of hsa-miR-146a-5p in plasma-derived exosomes of patients with diffuse large B-cell lymphoma. 2019 , 24, 10	10
564	Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India. 2019 , 8, 57-59	6
563	Diffuse large B-cell lymphoma: An institutional analysis. 2018 , 7, 200-202	11
562	Diffuse Large B-Cell Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up. 2019 , 7, 209-213	2
561	Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma. 2016 , 50, 96-103	11
560	Long Non-coding RNA HOTAIR Expression in Diffuse Large B-Cell Lymphoma: In Relation to Polycomb Repressive Complex Pathway Proteins and H3K27 Trimethylation. 2016 , 50, 369-76	21
559	A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma. 2017 , 51, 284-291	5
558	Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. 2017 , 51, 224-241	7
557	Prognostic Implication of Programmed Death-1-Positive Tumor-infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma. 2011 , 45, 573	2
556	Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. 2019 , 51, 919-932	8

555	The Diagnostic and Prognostic Impact of Serum miRNA-21 in a Sample of Hepatitis C/None Hepatitis Diffuse Large B Cell Lymphoma Egyptian Patients. 2017 , 07, 49-72	2
554	Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4. 2019 , 09, 121-143	1
553	Primary Gastric Diffuse Large B-Cell Lymphoma: Prognostic Factors in the Immuno-Oncology Therapeutics Era. 2020 , 37, 193-202	2
552	The current lymphoma classification: new concepts and practical applications triumphs and woes. 2012 , 32, 296-305	5
551	Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. 2020 , 10, 29-46	16
550	Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. 2016 , 6, 505-16	44
549	R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma. 2012 , 31, 306-14	9
548	Primary bone lymphoma. 2009 , 133, 1868-71	33
547	Best practices in contemporary diagnostic immunohistochemistry: panel approach to hematolymphoid proliferations. 2009 , 133, 756-65	30
546	Diffuse large B-cell lymphoma--more than a diffuse collection of large B cells: an entity in search of a meaningful classification. 2009 , 133, 1121-34	32
545	Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. 2009 , 133, 1233-7	42
544	Activation-induced cytidine deaminase expression in diffuse large B-cell lymphoma with a paracortical growth pattern: a lymphoma of possible interfollicular large B-cell origin. 2010 , 134, 449-56	5
543	Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. 2010 , 134, 759-65	8
542	Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. 2004 , 128, 1004-22	60
541	Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. 2006 , 130, 1707-11	24
540	Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. 2006 , 130, 1819-24	37
539	Primary testicular and paratesticular lymphoma: a retrospective clinicopathologic study of 34 cases with emphasis on differential diagnosis. 2007 , 131, 1040-6	19
538	Diffuse large B-cell lymphoma. 2008 , 132, 118-24	77

537	Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. 2008 , 132, 441-61	67
536	The immunohistochemistry laboratory: looking at molecules and preparing for tomorrow. 2010 , 134, 1659-65	23
535	Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis. 2012 , 13, 3037-46	17
534	Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?. 2016 , 17, 2285-9	9
533	Drug therapy for double-hit lymphoma. 2019 , 8,	5
532	Lymphomas in Ile-Ife, Nigeria: Immunohistochemical Characterization and Detection of Epstein-Barr virus Encoded RNA. 2015 , 9, EC14-9	3
531	Diffuse Large B-Cell Lymphoma of Maxilla - A Case Report of Late Relapse. 2016 , 10, ZD12-4	3
530	Clinicopathological analysis of diffuse large B-cell lymphoma lacking surface immunoglobulin light chain restriction on flow cytometry. 2021 ,	0
529	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma. 2021 , 61,	
528	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. 2021 ,	2
527	Precision diagnostics in lymphomas - Recent developments and future directions. 2021 ,	0
526	Oncogenic role of SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2 positive diffuse large B-cell lymphomas. <i>Blood</i> , 2021 ,	2.2 0
525	Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. 2021 , 14, 629	
524	A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of DLBCL. 2021 ,	2
523	The role of B-expression in diffuse large B-cell lymphoma. 2021 , 20, 13-20	0
522	Large B-cell lymphoma with IRF4 rearrangement. 2021 , 66, 445-457	
521	The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. 2021 , 1	1
520	Diffuse Large B-Cell Lymphoma Revealed by Splenic Abscess: A Case Report. 2021 , 13, e18771	0

519	Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma. 2021 ,	1
518	Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. 2021 , 1-8	1
517	Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology. 2022 , 61, 27-36	0
516	Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. 2021 , 1	0
515	Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma. 2021 ,	2
514	Deciphering genes associated with diffuse large B-cell lymphoma with lymphomatous effusions: A mutational accumulation scoring approach. 2021 , 9, 74	1
513	References. 2004 , 379-401	
512	Non-Hodgkin lymphomas. 2004 , 575-616	
511	Biological Therapy of Non-Hodgkin's Lymphomas. 2006 , 249-277	
510	Nodale aggressive Non-Hodgkin-Lymphome. 2006 , 2987-3047	
509	Non-Hodgkin's Lymphomas of Childhood. 2006 , 502-525	
508	Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin. 2007 , 131, 457-67	3
507	Lymphomas including Hodgkin lymphoma. 2008 , 1151-1165	
506	Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. 2008 , 2008, 286-287	
505	A case of diffuse large B-cell lymphoma hardly differentiating from high-grade urothelial carcinoma in cytology. 2008 , 47, 296-300	
504	A case of intraocular malignant lymphoma diagnosed by cytology obtained from surgically removed vitreous. 2008 , 47, 437-441	
503	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. 2008 , 2008, 280-281	
502	Hematologic malignancies: correlation between morphology, phenotype,. 2008 , 125-242	

- 501 Differential diagnosis [Chromosomal/molecular changes. **2008**, 542-566
- 500 [Molecular diagnosis of malignant lymphomas]. **2009**, 129, 2352-6
- 499 Lymphomas. **2009**, 830-843
- 498 Monoclonal Antibody Therapy for Hematologic Malignancies. **2010**, 493-536
- 497 Developing Prognostic Models for Diffuse Large B-cell Lymphoma. **2010**, 553-561
- 496 Cutaneous infiltrates [Lymphomatous and leukemic. **2010**, 971-1005.e30 1
- 495 A CASE REPORT OF PRIMARY MALIGNANT LYMPHOMA OF THE APPENDIX TREATED BY SURGERY AND POST-OPERATIVE CHEMOTHERAPY. **2010**, 71, 736-741
- 494 Localisation uro-ghitale. **2010**, 61-67
- 493 Myelodysplastic Syndromes and Chronic Myeloproliferative Neoplasms. **2010**, 293-312
- 492 Molecular Pathology of Mature B-Cell and T-Cell Lymphomas. **2011**, 157-214
- 491 MicroRNAs in Lymphoma. **2011**, 239-267 1
- 490 Primary Cutaneous B-Cell Lymphoma. **2011**, 306-318
- 489 Lymphomas of Bone. **2011**, 327-339 1
- 488 Association of CD57+ Natural Killer Cells with Better Overall Survival in DLBCL Patients. **2011**, 45, 361 0
- 487 CD44s and CD44v6 Are Predominantly Expressed in the Non-germinal Center B-Cell-like Type of Diffuse Large B-Cell Lymphomas. **2011**, 45, 589
- 486 Diffuse large B-cell lymphoma of the vagina. **2011**, 50, 360-365
- 485 Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma. **2010**, 2011, 563216 2
- 484 Diffuse Large B-Cell Lymphoma. 134-154 6

483 Childhood Lymphoma. **2012**, 101-124

482 Primary CNS Lymphoma: Immunohistochemistry of BCL-6 and Treatment with High-Dose Methotrexate. **2012**, 41-44

481 Hematopoietic Tumors of the Breast. **2012**, 740-766

480 Non-Hodgkin's Lymphoma. **2012**, 1545-1572

479 Association of Morphology and Immunophenotype in Diffuse Large B-Cell Lymphomas with Bone Marrow Infiltration in a Sample Mexican Population. **2012**, 02, 29-37

478 Where Do We Stand in the Genomics of Lymphomas?. **2013**, 495-541

477 Prognostic Factors in B-Cell Lymphomas. **2013**, 101-139

476 Lymphome diffus ^ grandes cellules B. **2013**, 65-81

475 Genomic Analysis of B-Cell Lymphomas. **2013**, 35-51

474 Cell Origin Subtypes Predict Outcomes in Localized-Stage Diffuse Large B-Cell Lymphoma Treated with Curative Radiotherapy. **2013**, 04, 475-484

473 Diffuse Large B-Cell Lymphoma. **2013**, 177-202

472 Diagnostic Immunohistochemistry in Tumor Metastasis. **2013**, 279-284

471 Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. **2013**, 32, 561-6

470 The usefulness of pleural effusion cytology in primary cardiac lymphoma^| ^mdash;A case report^| ^mdash;. **2014**, 53, 23-27

469 Primary central nervous system lymphoma in Miyazaki, southwestern Japan, a human T-lymphotropic virus Type-1 (HTLV-1)-endemic area: clinicopathological review of 31 cases. **2014**, 54, 179-85

468 CNS Lymphoma. **2014**, 207-223

467 MicroRNAs and Blood Cancers. **2014**, 129-153

466 Primary Malignant Lymphoma of Prostate with Silent <i>>MYD</i></i>88 Mutation. **2014**, 03, 125-128

- 465 Hematolymphoid Lesions. **2015**, 323-388
- 464 [Primary hepatic lymphoma in a female patient with Sjögren's disease: A case report and literature review]. **2015**, 87, 90-94
- 463 Evolution of views on the morphological diagnosis of lymphomas. **2015**, 4, 69
- 462 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 461 Diagnosis of Diffuse Large B-Cell Lymphoma. **2015**, 213-221
- 460 B-Cell Non-Hodgkin's Lymphomas with a Blastic/Large-Cell Phenotype. **2016**, 1-20
- 459 Risk factors, etiology, and pathogenesis. **2016**, 11-20 2
- 458 Primary Central Nervous System Lymphoma. **2016**, 306-315
- 457 Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. **2016**, 70, 342-347 2
- 456 Pathology. **2016**, 1-25
- 455 Lymphoid and Hematopoietic Tumors of the Breast. **2016**, 725-741
- 454 BCL2 and BCL6 double-immunostaining for the diagnosis of Grade 1-2 follicular lymphoma. **2016**, 55, 231-238
- 453 A case of paresthesia of the contralateral mental region suspected to be an early symptom of diffuse large B-cell lymphoma. **2016**, 62, 163-168 1
- 452 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: CLINICOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL PROFILE. **2016**, 3, 1320-1325
- 451 B-Cell Non-Hodgkin's Lymphomas with a Blastic/Large Cell Phenotype. **2017**, 1617-1636
- 450 Primary Testicular Lymphoma. **2017**, 129-141 1
- 449 Diffuse Large B-Cell Lymphoma. **2017**, 29-43
- 448 Molecular Mechanisms in Non-Hodgkin Lymphoma. **2017**, 561-587

447 Diffuse large B-cell lymphoma. **2017**, 139-153

446 Infiltrative Rash Secondary to Leukemic-Phase Diffuse Large B-Cell Lymphoma With t(14;18), CDKN2A and MLL Deletion. **2017**, 6, 90-95

445 Case report. A rare case of triple-hit diffuse large B-cell lymphoma of the parotid gland in a patient with Sjogren's syndrome. **2017**, 7, 103-107

444 Primary Cutaneous Diffuse Large B-Cell Lymphoma – Case Report. **2017**, 9, 57-62

443 FOXP3-positive regulatory T cells are correlated with improved survival in diffuse large B-cell non-Hodgkin lymphoma. **2017**, 37, 104-111

442 Diffuse Large B-Cell Lymphomas in Older Adults. **2018**, 1-31

441 Diffuse Large B-Cell Lymphoma. **2018**, 770-775

440 Contribution of Immunohistochemistry in the Diagnosis of Lymphomas. **2018**, 08, 17-25

o

439 Thymic Tumors and Lymphomas: The Clinical Impact of Their Underlying Molecular Features. **2018**, 129-161

438 Lymph Node Cytology. **2018**, 259-288

437 PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. **2018**, 1, 26-33

436 Thyroid Lymphoma. **2018**, 308-309

435 Lymphoma, Thyroid. **2018**, 274-279

434 A prize-collecting Steiner tree application for signature selection to stratify diffuse large B-cell lymphoma subtypes.

1

433 Association of ERCC2 Gene Polymorphisms with Susceptibility to Diffuse Large B-Cell Lymphoma. **2018**, 24, 7015-7022

1

432 Großzellige und aggressive B-Zell Lymphome. **2019**, 601-624

431 A Case of Primary Cutaneous Diffuse Large B-cell Lymphoma with Localized Cutaneous Nodular Amyloidosis. **2018**, 80, 460-465

430 Aggressive Lymphoma. **2019**, 387-399

429	Epidemiology, pathogenesis, molecular characteristics, classification and prognosis of the diffuse large B-cell lymphoma. 2018 , 36-40	0
428	Significance of oncogenic MYD88 and CD79B mutations in B-cell lymphomas. 2018 , 21, 81-89	1
427	Aggressive Lymphoma in Children and Adolescents. 2019 , 245-282	
426	Diffuse large B-cell lymphoma presenting with gastrocolic fistula and successfully treated with R-CHOP chemotherapy. 2018 , 21, 70-79	0
425	Evaluation of a case of diffuse large B-cell lymphoma. 2019 , 23, 7-11	2
424	????????????????????????????????????B?????????. 2019 , 28, 113-118	
423	Pathology of Lymphoreticular Tissues. 2019 , 265-314	
422	Primary mediastinal large B-cell lymphoma. 2019 , 48, 49-52	
421	The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. 2019 , 10, 53-68	
420	Intravascular Large B-cell Lymphoma Diagnosed by Detection of the MYD88 Gene Mutation. 2019 , 67, 585	
419	An Abrupt Nodular Eruption in an Elderly Man. 2019 , 299-306	
418	Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results. 2019 , 36, 81-87	1
417	Immunophenotypic characteristics of diffuse large b-cell lymphoma and expression of C-MYC protein: single Ecuadorian center experience. 2019 , 23, 41-44	
416	Primary Bone Lymphomas: Long-Term Results of a Prospective Single-Center Trial. 2019 , 12, 247-262	2
415	Antitumor effects and mechanisms of 1,25(OH) ₂ D ₃ in the Pfeiffer diffuse large B lymphoma cell line. 2019 , 20, 5064-5074	1
414	A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of Diffuse Large B-cell Lymphoma.	1
413	Lymphoid Neoplasms of the Kidney. 2020 , 239-259	
412	Lymph Nodes and Spleen. 2020 , 65-100	

411 Hematolymphoid Tumors. **2020**, 213-225

410 Prognostic Impact of Immunohistochemical and Molecular Features of Diffuse Large B-cell Lymphoma. **2019**, 2, 5-7

409 Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level.

408 Recurrence of diffuse large B-cell lymphoma recurring in the ileum 10 years after complete remission: A case report. **2019**, 95, 78-80

407 Large B-Cell Lymphoma. **2020**, 123-155

406 Primary Cutaneous B-cell Lymphomas: FL, MCL, Differential Diagnosis. **2020**, 95-113

405 Nodal Malignant Lymphoma (With Comments on Extranodal Malignant Lymphoma and Metastatic Cancer). **2020**, 427-447

404 Current Topics in Malignant Lymphomas : Knowledge of Malignant Lymphomas that Surgeons Should Know. **2020**, 71, 71-77

403 The prognostic importance of double-expressor subgroup and AID , UNG and mismatch repair protein expressions in diffuse large B-cell lymphomas.

402 Intra-tumor heterogeneity of Diffuse Large B-cell Lymphoma involves the induction of diversified stroma-tumor interfaces.

401 Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse-a case report. **2020**, 32, 22 1

400 Primary mediastinal large B-cell lymphoma: the importance of genetic changes. **2020**, 14, 117-121 1

399 Epigenetic suppression of SLFN11 in germinal center B cells in the process of the dynamic expression change during B-cell development. 0

398 Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma. **2020**, 20, 93 1

397 MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single centre experience.

396 Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. **2021**, 1 1

395 Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. **2021**, 2

394 Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL. **2021**, 13, e2021063 1

- 393 Update on Novel Therapeutics for Primary CNS Lymphoma. **2021**, 13, 6
- 392 Cost Analysis of R-CHOP Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. **2020**, 2, 117-124 1
- 391 Case report of surgically treated primary breast lymphoma in a very elderly patient. **2020**, 1, e0038
- 390 Central Nervous System Lymphomas. **2020**, 26, 1476-1494 2
- 389 Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. **2021**, 62, 1107-1115 0
- 388 Lymphomas of the Gastrointestinal Tract. **2021**, 521-541
- 387 Expression and Prognosis of MYD88 L265p Mutation in Diffuse Large B-Cell Lymphoma. **2020**, 10, 133-139
- 386 Lymphoid Pathology on Small Biopsies (FNA and Small Core) [Advantages and Limitations: Guidelines for Ancillary Studies According to Clinical Scenario and Morphology. **2020**, 53-85
- 385 Prognostic Significance of BCL2 Protein in Diffuse Large Cell Lymphoma of Head and Neck; Relation to Response to Chemotherapy. **2020**, 10, 76-92
- 384 Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma. **2019**, 19, 2047-2059 0
- 383 Malignant Hematopoietic Disorders of the Mediastinum. **2020**, 1071-1119
- 382 Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma. **2020**, 60, 87-96 0
- 381 Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the SUVmax method. **2021**, 1-4
- 380 Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China. **2021**, 11, 754180 0
- 379 Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. **2021**, 14
- 378 Fibrin-Associated Diffuse Large B Cell Lymphoma Found on Revision Arthroplasty of the Knee. **2021**, 114, 708-713 0
- 377 The Non-Hodgkin's Lymphomas. **2006**, 1256-1284
- 376 Pathologic and Molecular Techniques Used in the Diagnosis and Treatment Planning of Sarcomas. **2006**, 13-34

375	Other Tumors of the Cervix (Melanocytic, Germ Cell, Trophoblastic, Lymphoid, and Myeloid Tumors). 2021 , 283-322	
374	MYC, BCL2 and BCL6 co-localisation patterns at single-cell resolution underlie their prognostic significance in diffuse large B-cell lymphoma.	
373	Secondary Involvement of the Uterine Cervix by Nongynecologic Neoplasms: A Detailed Clinicopathologic Analysis. 2020 , 44, 1699-1711	
372	Tumors of muscle, cartilage, and bone. 2010 , 851-881	
371	Differential diagnosis of aggressive neoplasms with plasmablastic and late post-follicular differentiation. 2020 , 26, 421-439	
370	A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas. 2021 , 45, 356-364	7
369	Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival. 2007 , 3, 399-420	27
368	Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. 2007 , 2, 403-17	
367	An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 2010 , 3, 430-6	8
366	A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. 2010 , 10, 8	33
365	Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature. 2010 , 4, 190-6	9
364	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. 2011 , 2, 245-52	7
363	Subtle bone marrow involvement by large B-cell lymphoma with pronormoblast-like morphology and prominent but not exclusive sinusoidal distribution. 2012 , 2, 113-8	3
362	Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. 2013 , 25, 95-101	3
361	Primary gastrointestinal lymphoma. 2012 , 17, 487-90	6
360	Primary central nervous system lymphoma in immunocompetent individuals: a single center experience. 2013 , 6, 1068-75	13
359	New Challenges in the Management of Diffuse Large B-Cell Lymphoma. 2012 , 2, 68-73	2
358	Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma. 2014 , 26, 459-65	4

357	The gene expression patterns of BMPR2, EP300, TGF β , and TNFAIP3 in B-Lymphoma cells. 2014 , 11, 202-7	
356	Intravascular large B-cell lymphoma manifesting as cholecystitis: report of an Asian variant showing gain of chromosome 18 with concurrent deletion of chromosome 6q. 2014 , 7, 8181-9	6
355	Primary non-hodgkin lymphoma of the stomach: clinicopathological characteristics and prognostic factors in Iranian patients. 2014 , 7, 219-24	2
354	Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. 2015 , 8, 275-86	4
353	Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature. 2015 , 8, 7594-9	4
352	Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study. 2015 , 8, 9676-83	1
351	Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis. 2015 , 8, 10705-13	15
350	MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma. 2015 , 8, 13043-50	6
349	Intravascular lymphoma of the central nervous system presenting as multiple cerebral infarctions. 2012 , 74, 353-8	11
348	miR-4284 and miR-4484 as Putative Biomarkers for Diffuse Large B-Cell Lymphoma. 2016 , 41, 334-9	18
347	Primary Diffuse Large B-cell Lymphoma of the Breast: A Rare Case and Review of Literature. 2017 , 38, 244-247	3
346	Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis. 2017 , 16, 1233-1248	2
345	Molecular Subtypes, Apoptosis and Proliferation Status in Indonesian Diffuse Large B-Cell Lymphoma Cases. 2018 , 19, 185-191	2
344	Nuances in the Management of Aggressive Lymphomas. 2017 , 8, 279-284	
343	Correlation between Immunohistochemical Subtype and Clinicopathological Features in Patients with Diffuse Large B-cell Lymphoma. 2017 , 43, 253-257	
342	Prognostic significance of immunohistochemical subtypes based on the stage of B-cell differentiation in primary CNS lymphoma. 2019 , 12, 1457-1467	1
341	The impact of protein expression and gene abnormality on primary central nervous system diffuse large B-cell lymphoma. 2019 , 12, 2215-2223	4
340	Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma. 2018 , 11, 4472-4482	

- 339 Spinal lesion as the first manifestation of high-grade B-cell lymphoma, with and rearrangements. **2017**, 10, 8858-8862
- 338 Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens. **2020**, 40, 361-369
- 337 [Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission]. **2016**, 37, 756-761 2
- 336 [Expression and prognostic value of CARD11 in diffuse large B cell lymphoma]. **2016**, 37, 30-4 2
- 335 [Testicular lymphoma: a clinicopathological study of 65 cases]. **2015**, 36, 765-9 0
- 334 [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas]. **2017**, 38, 505-510 1
- 333 [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL]. **2019**, 40, 589-593 0
- 332 Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. **2020**, 10, 97-108 3
- 331 Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls. **2020**, 12, 6751-6762
- 330 [The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma]. **2021**, 42, 151-157
- 329 [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma]. **2021**, 42, 487-494
- 328 Primary Cardiac Lymphoma: Three Case Reports and a Review of the Literature.. **2021**, 11, 120-132 0
- 327 Non-Hodgkin-Lymphome. **2022**, 195-203
- 326 Molecular Classification of Diffuse Large B-Cell Lymphoma. **2021**, 42, 356-359
- 325 Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. **2021**, 0
- 324 Cluster of Differentiation 274 Antigen Immunohistochemical Expression in Tumor and Peri-tumor Cells of Hodgkin and Non-Hodgkin Lymphoma and Clinicopathological Relation (Single-center Study). **2021**, 9, 1011-1018
- 323 Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. **2021**, 101, 349 1
- 322 Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma. **2021**,

321	Influence of Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. 2021 , 13,	0
320	Advances in Lymphoma Molecular Diagnostics.. 2021 , 11,	1
319	miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN.. 2021 , 10, 4905-4913	1
318	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. 2021 ,	2
317	Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders.	
316	Application of Hans Algorithm for Subcategorization of Diffuse Large B-Cell Lymphoma in Fine-Needle Aspiration Biopsy Cytology. 2021 , 1-9	1
315	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. 2021 , 1-11	0
314	Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Blood</i> , 2021 ,	2.2 0
313	Primary central nervous system lymphomas express immunohistochemical factors of autophagy. 2021 , 11, 22259	2
312	Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases. 2021 , 8,	1
311	Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients. 2021 , 1-10	0
310	Prognostic implications of tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population. 2021 ,	0
309	Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India.. 2021 , 11, 770747	1
308	Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. 2021 , 62,	
307	Diffuse Large B-cell Lymphoma Presenting as Peritoneal Lymphomatosis: A Case Report and Literature Review.. 2021 ,	
306	Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens. 2020 , 40, 361-369	1
305	Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma.. 2020 , 9, 6116-6127	
304	Mature Lymphoid Neoplasms. 2020 , 245-282	

303	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. 2021 , 10, 2003533	2
302	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.. 2022 , 480, 667	3
301	Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.. 2022 ,	1
300	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.. 2022 , 15, 2632010X211070774	
299	Deletion of murine leads to de-repression of via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma.. 2022 , 13, 267-281	
298	Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/transformation.. 2022 ,	0
297	Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.. 2022 , 101, 763	0
296	Primary Central Nervous System Lymphoma : An Update. 2022 , 31, 20-30	
295	Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.. 2022 , 1-4	0
294	CARD9 Forms an Alternative CBM Complex in Richter Syndrome.. 2022 , 14,	
293	Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.. 2022 , 39, 44	0
292	Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.. 2022 , 27, 57-66	0
291	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.. 2022 , 14,	
290	Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice.. 2022 , 24, 13	2
289	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.. 2022 , 1-6	
288	Primary adrenal diffuse large B-cell lymphoma with normal adrenal cortex function: A case report.. 2022 , 10, 709-716	
287	Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma.. 2022 , 18, 1313-1327	0
286	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.. 2022 , 101, 755	0

285	Prognostic significance of Bcl-2 expression in primary cutaneous B-cell lymphoma: a reappraisal. 2022 , 156,	
284	Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High-Grade B-Cell Lymphoma.. 2022 ,	
283	Primary diffuse large B-cell lymphoma of the head and neck in a Brazilian single-center study.. 2021 ,	
282	Clinical impact of central nervous system-directed therapies on intravascular large B-cell lymphoma: A single institution's experience.	1
281	Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the Lymphoma Registry.. 2021 , 11, 796962	0
280	Impact of Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. 2021 , JCO2102143	2
279	From inoperable to back to life: a case report of successfully treated obstructive right ventricular primary cardiac lymphoma.. 2022 , 6, ytac051	0
278	Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls.. 2022 , 29, 956-968	1
277	HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies.. 2022 , 58, 151913	0
276	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.. 2022 , 58, 151886	
275	Clinical Features and Prognostic Significance of Mutations in Diffuse Large B-Cell Lymphoma.. 2021 , 11, 746577	1
274	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.. 2021 , 13,	3
273	Prognostic impact of immunophenotyping of diffuse large B-cell lymphoma - a single-centre experience. 2022 , 67, 43-54	
272	Clinicopathologic features and outcomes of diffuse large B-cell lymphoma with extranodal involvement: A retrospective analysis. 2022 , 5, 67	
271	Recent advances in microfluidic devices for single-cell cultivation: methods and applications.. 2022 ,	3
270	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.. 2022 , 13, 1388-1397	0
269	Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers.. 2022 , 12, 790720	0
268	Clinical and Survival Outcomes in Patients with Supra-Diaphragmatic Vs Infra-Diaphragmatic Diffuse Large B Cell Lymphoma. 00,	

267	CD37 expression in follicular lymphoma.. 2022 , 101, 1067	1
266	A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome.. 2022 ,	1
265	Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review.. 2022 , 50, 3000605221081672	1
264	Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas. 2022 , 3, 174-187	
263	Efficacy and Safety of Cyclophosphamide Low-Dose Pre-Phase Chemotherapy in Diffuse Large B Cell Lymphoma with Gastrointestinal Involvement.. 2022 , 14, e2022017	
262	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.. 2022 , 11,	0
261	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.. 2022 , 14,	2
260	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma.. 2022 ,	3
259	The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China.. 2022 , 233, 153860	1
258	Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.. 2022 , 1	0
257	Optical Coherence Tomography Benefits the Diagnosis and Follow-Up of Primary Central Nervous System Lymphoma with Intraocular Involvement.. 2022 , 14, 1007-1018	0
256	CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: A histopathological study of 118 cases.. 2022 ,	0
255	CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.. 2022 ,	0
254	Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin.. 2022 , 6, e705	
253	Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity.. 2022 , 14,	0
252	Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma.. 2022 , 14,	0
251	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.. 2022 , 231, 153804	2
250	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.. 2022 , 13, 842439	0

249	Case 7-2022: A 65-Year-Old Woman with Depression, Recurrent Falls, and Inability to Care for Herself.. 2022 , 386, 977-986	0
248	Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma.. 2022 , 1-9	
247	DLBCL 1L-What to Expect beyond R-CHOP?. 2022 , 14,	
246	Inferring gene expression from cell-free DNA fragmentation profiles.. 2022 ,	5
245	MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP.. 2022 , 14, 925-935	1
244	Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach.. 2022 ,	
243	Protein kinase c delta expression in primary central nervous system lymphomas. 1	
242	Ki67 Immunohistochemical Expression Level $\geq 70\%$, Bulky Presentation ≥ 7.5 cm, Meningeal Lymphomatosis, and Interim PET SUVmax After 4 Treatment Cycles $\geq 71\%$ as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.. 2022 , 14, 1000-1007	1
241	Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.. 2022 , 14,	1
240	Identifying novel disease genes based on protein complexes and biological features. 2021 ,	
239	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.. 2021 , 11,	
238	Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology. 2021 , 11, 23823	0
237	A Review of Results from Clinical Trials Based on Co-Variants of the R-CHOP Regimen in Untreated Patients with Diffuse Large B-cell Lymphoma. 2021 , 14, 117-123	
236	Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.. 2021 , 11,	2
235	Successful Outcome of Patellectomy Plus Chemotherapy for Primary Bone Lymphoma of the Patella: A Case Report and Literature Review.. 2021 , 11, 786495	
234	Smoothed (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling. 2021 ,	1
233	Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.. 2021 , 1-5	0
232	Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.. 2021 , 1-12	1

- 231 Epstein-Barr Virus-Positive Diffuse Large B Cell Lymphoma. 27-46 o
- 230 Epidemiology, Pathogenesis, Molecular Characteristics, Classification, and Prognosis of Diffuse Large B-Cell Lymphoma: New Views on the Existing Problems. **2020**, 217-225
- 229 Central nervous system manifestations of hematological malignancies: Our spectrum over 3 years. **2021**, 4, 1
- 228 Dynamic Change of Soluble Interleukin-2 Receptor Distinguished Diffuse Large B-Cell Lymphoma with Prognostic Significance and Tumor Microenvironment.
- 227 Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1 β intersect to regulate angiogenesis in B-cell lymphoma.. **2022**, 1
- 226 Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.. **2022**, o
- 225 Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.. **2022**, 13, 846357
- 224 Bone marrow. 813-942
- 223 The stomach. 1853-1924
- 222 Treatment approach to diffuse large B-cell lymphomas. 286-307
- 221 Table_1.DOCX. **2020**,
- 220 Table_2.DOCX. **2020**,
- 219 Table_4.DOCX. **2020**,
- 218 Image_1.PNG. **2020**,
- 217 Image_2.PNG. **2020**,
- 216 Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.. **2022**, o
- 215 Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.. **2022**,
- 214 [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].. **2021**, 42, 917-922

- 213 [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].. **2022**, 43, 41-47
- 212 Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts.. **2022**, ○
- 211 A Case of Primary Cardiac Lymphoma Arising from Both Sides of the Heart.. **2022**,
- 210 Posttransplant lymphoproliferative disorder in a kidney transplant recipient: a case of Epstein-Barr virus-positive primary central nervous system lymphoma.
- 209 T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.. **2022**, 13, 873789 1
- 208 Unusual presentation of primary ovarian diffuse large B-cell lymphoma: a case report.. **2022**, 15, 47 ○
- 207 Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment. **2022**, 12, 1087 1
- 206 Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.. **2022**, 1-8
- 205 CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain.. **2022**, ○
- 204 CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.. **2022**, 14, ○
- 203 A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020. **2022**, 105565 1
- 202 The genomic and transcriptional landscape of primary central nervous system lymphoma.. **2022**, 13, 2558 4
- 201 Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.. **2022**, ○
- 200 Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.. **2022**, ○
- 199 Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.. **2022**,
- 198 Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. **2022**, 13,
- 197 Specific location of ocular adnexal lymphoma and mortality: an international multicentre retrospective study.. **2022**, ○
- 196 Case 14-2022: A 57-Year-Old Man with Chylous Ascites.. **2022**, 386, 1834-1844

- 195 Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.. **2022**, 1
- 194 An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.
- 193 Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.. **2022**,
- 192 The Stem Cell Continuum Model and Implications in Cancer. **2022**, 1-24
- 191 Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma. **2022**, 12, 1106 ○
- 190 Enhancement of the International prognostic index with β_2 -microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. **2022**, 22, ○
- 189 Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma. **2022**, 13, ○
- 188 Clinical practice of precision medicine in lymphoma. **2022**, 2,
- 187 Primary non-Hodgkin lymphoma of the extra-hepatic bile duct: A case report. **2022**, 17,
- 186 Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma. 12, 1
- 185 Biosimilar Rituximab (Reffitux) Added to CHOP Chemotherapy for De-novo Diffuse Large B-cell Lymphoma Patients: Real-life Single Center Experience.
- 184 Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era. **2022**, 532, 72-78
- 183 Cutaneous Lymphomas. **2022**, 833-896
- 182 Bone Marrow. **2022**, 799-831
- 181 Revising the Treatment Pathways in Lymphoma: New Standards of Care How Do We Choose?. **2022**, 1-14 ○
- 180 NF- κ B Signaling Pathway and Efficacy of Bortezomib-Based Combination Chemotherapy in Patients with Non-Hodgkin's Lymphoma. **2022**, 18, 850-855
- 179 Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters. 12, ○
- 178 Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma. **2022**, 17, e0269570 1

177	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.	49
176	Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib: A Case Report. 2022 ,	0
175	R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. 2022 ,	1
174	An Autophagy-Related Gene Signature can Better Predict Prognosis and Resistance in Diffuse Large B-Cell Lymphoma. 13,	0
173	Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma.	0
172	Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.	0
171	Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report. 2022 , 24,	
170	Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma. Volume 15, 2039-2049	
169	Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study. 2022 , 3, e481-e490	0
168	Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint).	
167	Orofacial intramuscular lymphoma: first presentation. 014556132211019	
166	Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. OF1-OF11	1
165	Clinical Impact of the Histopathological Index and Neuroimaging Features Status in Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Analysis of 51 Cases. 12,	
164	Proposal of Diagnostic Approach of Periodontal Primary Non Hodgkin Lymphoma of Bone with Flow Cytometry as an Essential Diagnostic Component.	0
163	Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. 107815522211104	
162	A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China. 13,	
161	Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells. 2022 , 23, 7874	
160	Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma. 2005 , 11, 1065-1072	36

- 159 A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma. 12,
- 158 Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report. **2022**, 10, 7994-8002
- 157 Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. **2022**, 36, 2151-2164 1
- 156 Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.. **2022**, Publish Ahead of Print,
- 155 A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma. 1-4
- 154 Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study.
- 153 Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. 0
- 152 Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. 2
- 151 Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma. **2022**, 43, 99-106
- 150 Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era. 12,
- 149 Primary hepatic lymphoma diagnosed with diffuse large B cell lymphoma originating from a germinal center B cell. **2022**, 63, 381-387
- 148 Analysis of the Diagnosis of Burkitt-Like Lymphoma in a Patient With Atypical Cytogenetics and Molecular Markers. **2022**,
- 147 Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. 1
- 146 The Methylation of the p53 Targets the Genes MIR-203, MIR-129-2, MIR-34A and MIR-34B/C in the Tumor Tissue of Diffuse Large B-Cell Lymphoma. **2022**, 13, 1401 0
- 145 Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. **2022**, 28,
- 144 Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. 13, 1
- 143 Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. 12,
- 142 Nodular lymphocyte-predominant Hodgkin lymphoma and clinical impact of its variant histology: a clinicopathologic study from tertiary cancer centre in India.

- 141 Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma. Publish Ahead of Print,
- 140 The Era of Genomic Research for Lymphoma: Looking Back and Forward. **2022**, 3, 485-507
- 139 Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. **2022**, 62, 175-180 ○
- 138 Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint). ○
- 137 A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma. ○
- 136 Tumors of Hematopoietic and Lymphoid Origin. **2022**, 559-585 ○
- 135 Diffuse Large B-Cell Lymphomas: From Morphology to Genomic Profiling. ○
- 134 Prognostic factors in primary central nervous system lymphoma. Publish Ahead of Print, ○
- 133 Visceral fat area and albumin based nutrition-related prognostic index model could better stratify the prognosis of diffuse large B-cell lymphoma in rituximab era. 9, ○
- 132 ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma. **2022**, 14, 4650 ○
- 131 Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy. **2022**, 17, e0273408 ○
- 130 CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma. ○
- 129 A Multicenter Study of Clinicopathology and Immunohistochemical Distinction between Adult and Pediatric Large B-Cell Lymphoma. 1-12 1
- 128 Increasing tissue requirements in lymphoma trials may exclude patients with high risk disease or worse prognosis. ○
- 127 Overexpression of interleukin-20 correlates with favourable prognosis in diffuse large B-cell lymphoma. **2022**, ○
- 126 DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis. **2022**, 101, e30620 ○
- 125 Detection of DLBCL by pixel purity index and iterative linearly constrained minimum variance into hyperspectral imaging analysis. ○
- 124 A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China. Volume 14, 2711-2721 ○

- 123 Practical approach to gastrointestinal system lymphoproliferative lesions. **2022**, 31, 213-230 ○
- 122 Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China. 12, ○
- 121 Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies. **2022**, 23, 1443-1456 ○
- 120 Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP. **2022**, 15, 805-812 ○
- 119 Double/triple hit lymphoma in the gastrointestinal tract: clinicopathological features, PD-L1 expression and screening strategy. ○
- 118 Diffuse large b-cell lymphoma of the ocular adnexa with flow cytometry analysis and review of the literature. 112067212211270 ○
- 117 Ocular adnexal lymphoma: Subtype-specific clinical and genetic features. **2022**, 100, 3-37 ○
- 116 Genetic and phenotypic characterisation of HIV -associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. ○
- 115 Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. **2022**, ○
- 114 Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis. **2022**, ○
- 113 Double expressor Diffuse large B-cell lymphoma: A case report and literature review. **2022**, 75, 106-110 ○
- 112 Non-Hodgkin's Lymphoma. 1-20 ○
- 111 The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. 12, ○
- 110 Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options. ○
- 109 Immense Tumor of Maxillary Sinus with Exophthalmos A Rare Underlying Cause. **2022**, 14, 305-309 ○
- 108 Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF- κ B and Immune Checkpoints. Publish Ahead of Print, ○
- 107 Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. ○
- 106 Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. ○

- 105 5-Hydroxymethylation alterations in cell-free DNA reflect molecular distinctions of diffuse large B cell lymphoma at different primary sites. **2022**, 14, ○
- 104 Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018). **2022**, ○
- 103 Circular RNA circ_0000877 serves as a miR-671-5p sponge to regulate diffuse large B-cell lymphoma development via HK2. ○
- 102 Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials. ○
- 101 The multilobated morphology is still a better prognosis factor of diffuse large B-cell lymphoma in the R-CHOP era. 1
- 100 The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?. **2022**, 17, ○
- 99 Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment. **2022**, 3, 650-662 ○
- 98 Different expression of DNMT1, PCNA, MCM2, CDT1, EZH2, GMNN and EP300 genes in lymphomagenesis of low vs. high grade lymphoma. **2022**, 239, 154170 ○
- 97 High-Grade B-cell Lymphomas. **2022**, 5, 41-50 ○
- 96 Extracellular Vesicles in Diffuse Large B Cell Lymphoma: Characterization and Diagnostic Potential. **2022**, 23, 13327 ○
- 95 The Stem Cell Continuum Model and Implications in Cancer. **2022**, 1255-1278 ○
- 94 Utility of reverse transcriptase [Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO). **2022**, 0 ○
- 93 EpsteinBarr Virus: A Biological Overview and Clinicopathological Changes of Two EpsteinBarr Virus-Related Lymphoproliferative Disorders in a World Health Organization (WHO) 2017 Report. 99-107 ○
- 92 Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy. 1-11 ○
- 91 Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition. ○
- 90 The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study. **2022**, 22, ○
- 89 Activated B-cell signet ring lymphoma: A case report and a comparative review of the literature. **2022**, 30, 300682 ○
- 88 Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma. 12, ○

- 87 Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis. 13, ○
- 86 Primary lymphoma of the uterine cervix: a clinicopathologic study of 13 cases with review of additional 54 cases in the literature. ○
- 85 Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. **2022**, 13, 1237-1244 ○
- 84 Management of B-Cell Lymphoma: Where Are We Now and Where Are We Going?. 38-45 ○
- 83 Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma. ○
- 82 Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients. **2022**, 2022, 1-11 ○
- 81 Germinal Center-Derived Diffuse Large B-cell Lymphomas with Aberrant Co-expression of MUM1 in Adults and Children. **2022**, 11, 1-6 ○
- 80 Clinical impact of 5?MYC or 3?MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas. **2023**, 272-273, 1-8 ○
- 79 Malignant Lymphoma [A Changing Spectrum. **2009**, 38, 837-839 ○
- 78 Advances in the Treatment of Non-Hodgkin B Lymphoma: Exploring New Frontiers. 38-46 ○
- 77 Double-Hit and Triple-Hit Lymphomas: New Perspectives for Their Classification. 95-103 ○
- 76 Lymphoid and Hematopoietic Tumors of the Breast. **2022**, 805-824 ○
- 75 Hematolymphoid Neoplasms of Bone. **2021**, 549-592 ○
- 74 Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas. **2022**, ○
- 73 A series of heterogeneous lymphoproliferative diseases with CD3 and MUM1 co-expressed in cats and dogs. **2023**, 35, 22-33 ○
- 72 Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities. ○
- 71 Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. Volume 15, 1481-1501 ○
- 70 Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years. 35, ○

69	Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. 2022 , 11, 7162	1
68	Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma. 2022 , 27, 1272-1281	0
67	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.	2
66	Sequencing therapy in relapsed DLBCL. 2022 , 2022, 146-154	0
65	High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.	0
64	Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma. 2022 , 12,	0
63	CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study. 2022 , 15, 203-213	0
62	The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma. 2023 , 7, e822	0
61	Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.	0
60	Evaluation of a convolution neural network for baseline total tumor metabolic volume on [18F]FDG PET in diffuse large B cell lymphoma.	0
59	Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis. 039361552211497	0
58	Biallelic $t(3;14)(q27;q32)$ and $t(3;22)(q27;q11)$ rearrangements by dual $t(3;14)(q27;q32)$ and $t(3;22)(q27;q11)$ translocations in diffuse large B-cell lymphoma. 2022 , 62, 268-272	0
57	Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimens.	0
56	The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma. 2023 , 18, e0280044	0
55	Genetic Profiling in Diffuse Large B-Cell Lymphoma: The Promise and the Challenge. 2023 , 36, 100007	0
54	Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma. 2023 , 12, 196	0
53	RNA Extraction Method Impacts Quality Metrics and Sequencing Results in Formalin-Fixed, Paraffin-Embedded Tissue Samples. 2023 , 100027	0
52	Prognostic Significance of p53 and p63 in Diffuse Large B-Cell Lymphoma: A Single-Institution Experience. 2023 , 30, 1314-1331	0

- 51 Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study. ○
- 50 Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma. ○
- 49 CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study. **2022**, ○
- 48 Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival. Volume 15, 1583-1595 ○
- 47 Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma. **2023**, ○
- 46 Primary Esophageal Lymphoma: A Histopathological Experience from Two Tertiary Hospitals, Western Saudi Arabia. **2023**, 2023, 1-6 ○
- 45 Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). **2023**, 14, 57-70 ○
- 44 Molecular classification and therapeutics in diffuse large B-cell lymphoma. 10, ○
- 43 Identification of MYC/BCL2 Double-expressers Lymphomas in Diffuse Large B Cell Lymphoma Patients and Association with their Prognostic Parameters and Survival Rates: A Single Centre Experience. **2022**, 18, 87-92 ○
- 42 Ras interacting protein 1 facilitated proliferation and invasion of diffuse large B-cell lymphoma cells. **2023**, 24, ○
- 41 Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma. **2023**, 12, ○
- 40 Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms Updated Classification and New Concepts. **2023**, 15, 2285 ○
- 39 Immunohistochemical analysis of arachidonate 5-lipoxygenase expression in B-cell lymphomas: Implication for B cell differentiation and its analogy with lymphomagenesis. **2023**, 242, 154328 ○
- 38 A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma. 29, ○
- 37 Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma. **2023**, 15, 952 ○
- 36 MYD88L265P and MYD88 other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma. ○
- 35 In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines. **2023**, 12, 596 ○
- 34 Is the Hans algorithm outdated?. **2022**, 5, 792 ○

- 33 Distribution and clinical features of lymphomas involving skin in Taiwan. ○
- 32 MUM-1 in canine lymphoma: A pilot study. 030098582311554 ○
- 31 The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma. 14, ○
- 30 Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution. **2023**, 136, 167-175 ○
- 29 Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis. ○
- 28 Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer's ring in adults. **2023**, 482, 551-560 ○
- 27 Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL. Volume 15, 245-255 ○
- 26 Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. **2023**, ○
- 25 Prostate lymphoma with renal obstruction; reflections on diagnosis and treatment: Two case reports. 11, 1627-1633 ○
- 24 Non-germinal center B-cell subtype of pediatric diffuse large B-cell lymphoma in Japan: A retrospective cohort study. **2023**, 70, ○
- 23 Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis. **2023**, 11, 42 ○
- 22 Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the Detection of MYC and BCL2 (and BCL6) Rearrangements in Large B-Cell Lymphomas: Updates Amid the New WHO Classification of Lymphoid Neoplasms. ○
- 21 Investigating In Situ Expression of c-MYC and Candidate Ubiquitin-Specific Proteases in DLBCL and Assessment for Peptidyl Disruptor Molecule against c-MYC-USP37 Complex. **2023**, 28, 2441 ○
- 20 Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. ○
- 19 Case report: Complete atrio-ventricular block successfully reversed in newly diagnosed primary cardiac B-cell lymphoma. 10, ○
- 18 Diagnostic, Prognostic, and Predictive Role of Next-Generation Sequencing in Mature Lymphoid Neoplasms. **2023**, ○
- 17 MALT1-dependent cleavage of CYLD promotes NF- κ B signaling and growth of aggressive B-cell receptor-dependent lymphomas. **2023**, 13, ○
- 16 Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era. **2023**, ○

- 15 Clinical utility of positron emission tomography leading to rapid and accurate diagnosis of intravascular large B-cell lymphoma presenting with the central nervous system symptoms alone: A case report and review of the literature. 14, 89 ○
- 14 CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review. **2023**, ○
- 13 Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem). ○
- 12 Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study. ○
- 11 Klassifikation aggressiver B-Zell-Lymphome. ○
- 10 Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis. **2023**, 63, 19-24 ○
- 9 Histologic transformation of follicular lymphoma: pathologists' viewpoint. **2023**, 63, 12-18 ○
- 8 Clinico-Pathological, Cytogenetic and Molecular Profiles of Primary Cutaneous Diffuse Large B-Cell Lymphomas. **2023**, ○
- 7 A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis. 13, ○
- 6 A Comprehensive Study of the Immunophenotype and its Clinicopathologic Significance in Adult T-Cell Leukemia/Lymphoma. **2023**, 36, 100169 ○
- 5 SUV39H1 is a prognosis and immune microenvironment-related biomarker in diffuse large B-cell lymphoma. ○
- 4 Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. ○
- 3 An immunohistochemical study of double-expressor lymphomas and its correlation with cell of origin. **2023**, 19, 0 ○
- 2 Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma. 14, 160-170 ○
- 1 IRF4 rearrangement may predict favorable prognosis in children and young adults with primary head and neck large B-cell lymphoma. ○